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1. Introduction
Alzheimer´s  disease (AD) is  the most  prevalent  form of  dementia accounting for  60-70%
of  all  cases  worldwide.  As the world's  population ages  the  incidence of  AD is  expected
to  increase  rapidly  turning  into  a  global  epidemic  disease  with  incalculable  sociologi‐
cal and economic consequences. In 2006, the prevalence of AD worldwide was calculated
in  26.6  million  and  it  is  estimated  that  by  2050  current  prevalence  will  be  triplicated
or quadruplicated,  affecting 1 out of  85 persons worldwide [1,  2].  An accurate diagnosis
and  a  timely  detection  are  critical  for  improving  the  physical,  clinical,  emotional  and
financial  impacts  of  the  disease.  However,  this  aim  is  far  to  be  achieved  and  several
studies  indicate  that  less  than  35  percentage  of  people  living  with  AD  or  related
dementias  are  correctly  diagnosed  [3,  4].  As  a  consequence,  between  18%  and  67%  of
the  dementia  patients  are  treated  with  a  potentially  inappropriate  medication  [5].
In this dramatic scenario, new technical, methodological and notional approaches are explored
in order to overcome the inherent limitations in AD clinical diagnosis. Indeed, the identifica‐
tion of reliable diagnostic tools in AD remains impeded by the clinical, neuropathological and
molecular overlap existing between AD and other types of dementia such as Mild Cognitive
Impairment (MCI), or mixed forms of dementia, such as Vascular Dementia (VaD), Fronto‐
temporal Lobar Degeneration (FTLD) or Lewy Body Dementia (LBD), and by the high AD
heterogeneity according to disease onset, progression and duration [6-8].
Since the complexity of this scenario impairs the use of current diagnostic tools for a correct
data interpretation, in the recent years, new strategies such as the integrated and combined
use of neuropsychological profiles, imaging and biological fluids biomarkers have been
developed, improving current diagnosis classification [9-11] and predicting the conversion
from MCI to AD [12, 13].
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Despite recent solid advances in the topic, up to date, no single diagnostic tool or combination
of diagnostic tools can unequivocally confirm AD diagnosis. Indeed absolute confirmation and
definite AD diagnostic still requires histopathologic analysis on the post-mortem brain
certifying the presence of the pathologic disease hallmarks such as β-amyloid plaques and
neurofibrillary tangles.
Since AD is a progressive disease and no treatment is available to recover neuronal integrity,
the inaccuracy of AD early diagnosis and prognosis makes early therapeutic intervention
difficult and impedes the prevention of neurodegeneration and cognitive dysfunction.
Identification of disease specific clinical, imaging and biochemical-based tools at early stages
will help to greater extent to an early treatment which may restrain the disease progression.
Additionally, a thorough understanding of the role of biomarkers in AD disease and their
modulated levels in AD patients will facilitate the comprehension of their role in AD etiopa‐
thology and would help to establish a link between diagnostic and therapeutic fields. There‐
fore, the ultimate goal is to develop early and reliable diagnosis methods to establish an
appropriate and prompt treatment. Indeed this aspect is imperative to maximize the efficiency
of potential therapies and decrease symptomatology before pathological changes spread
throughout the brain and massive death of neurons has already occurred. Finally, it should
also be taken into consideration that the development of successful epidemiological risk
assessment and diagnosis programs, including a routinely monitoring of disease progression,
will need to be established through the development of new methodologies and protocols at
low cost and with non-invasive approaches.
The present chapter summarizes the most recent findings in the field of AD, including
neuropsychological profiles and brain and biological fluids biomarkers, which are currently
paving the way for new focused approaches in AD diagnosis and prognosis.
2. Diagnostic criteria/Clinical and research criteria
According to the International Classification of Diseases (ICD-10) and the Diagnostic and
Statistical Manual of Mental Disorders of the American Psychiatric Association (DSM IV)
dementia is defined as a a worsening of cognitive function from a preexisting individual level.
The major symptom is decline in memory and should be followed by at least one dysfunction
in another major cognitive core skill, severe enough to impair a person's ability to perform
everyday activities. The cognitive impairments should be irreversible and not be attributable
to e.g. a delirium or another psychiatric disorder and must be present for at least 6 month.
Moreover, the German Society of Psychiatry, Psychotherapy and Neurology (DGPPN) as well
as the German Neurological Society (DGN) refer to a subtle change in personality and behavior
in the process of dementia [14]. The criteria of the American National Institute of Neurological
and Communicative Disorders and Stroke/Alzheimer’s disease and Related Disorders
Association (NINCDS/ADRDA) are more often referred to in the literature, which differentiate
the degree of diagnostic accuracy in “possible” or “probable dementia” [15, 16].
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Based on the latter, commonly accepted dementia criteria, a “probable Alzheimer’s dementia”
(AD dementia) is diagnosed by signs of dementia on clinical examination and neuropsycho‐
logical tests whereby the memory impairment should be followed by another deficit in an
additional cognitive skill. In alternative there is impairment in two cognitive skills with a
recognized progression and without evidence of a reduced consciousness.
The age at onset should range between 40 and 90 years and other reasons for the cognitive
decline, e.g. treatable causes, should have been carefully ruled out in the diagnostic work up.
The clinical criteria of a “possible Alzheimer’s dementia” comprise a dementia syndrome of
untypical clinical presentation or duration in absence of other recognizable factors causative
of dementia, or if there is a progressive cognitive deficit without a recognized underlying
cause.
Exclusion criteria are referred to as sudden onset, focal neurological signs (hemiparesis,
hemianopsia) at onset as well as early appearance of gait disorders or epileptic fits.
This categorization is kept according to different revisions of the NINCDS/ADRDA-criteria
[16, 17]. Additionally, next to deficits in episodic memory, detection of specific biomarkers in
the cerebrospinal fluid (CSF) and imaging (Magnetic Resonance Imaging (MRI) and/or
Emission Computed Tomography (PET) is suggested which can increase sensitivity of AD
diagnosis.
Further supporting results are, e.g., a progressive worsening of specific cognitive function,
disabling in all-day activities, and occurrence of behavioral changes, a positive family history
of AD (especially if neuropathologically confirmed), a normal CSF result (basic analysis) and
unspecific electroencephalogram (EEG) changes.
A diagnosis of AD is compatible with plateaus during disease course, side symptoms as
depression, aggressive behavior, paranoia etc., neurological symptoms in progressed disease
state (myoclonus, gait problems, epileptic fits) and a normal Computerized Tomography (CT)-
scan [14].
While both terminologies: “probable AD”, “possible AD” are proposed for the clinical setting,
a third category of “probable and possible AD” was suggested for research purposes. Recent
research criteria for clinical AD diagnosis include next to mnestic deficits an occurrence of
deficits in non-mnestic function, e.g., language, visual-spatial orientation, executive function.
Furthermore, an early diagnosis of AD is proposed already during prodromal stages of
dementia, which refer to the clinical picture of a mild cognitive impairment (MCI) [18].
A MCI is a recognized risk factor for AD. Yet, there are presently no commonly agreed criteria
[14]. According to international consensus criteria, MCI is considered a condition between
normal and demented, a worsening of cognitive function (on self-observation or observation
by others) that can be demonstrated on neuropsychological tests, a worsening of cognitive
function during an observational time period during disease as well as conserved or only
minimally impaired dysfunction in complex all-day activities [19]. The difference between
MCI and dementia is based mostly on well-functioning in all-day activities. Standard meas‐
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urements for cognitive function comprise 1-1.5 standard deviation below the age- and
education-matched age group and a mini-mental status test of 24 or above points [18, 20].
The prevalence and conversion rates are variable according to the distinct examination setting.
In the clinical setting the annual conversion rate from MCI to AD has been calculated at around
10 percent [14, 21].
At present 4 different MCI subtypes are characterized: amnestic single domain, amnestic
multiple domains, non-amnestic single domain and non-amnestic multiple domains [20],
whereas the probability to develop AD is highest in MCI with memory deficits [14, 21].
3. Neuropsychological profiles
3.1. The neuropsychological profile of AD
AD is generally characterized by a slowly progressive preclinical (pre-symptomatical) state
over several years, an approximately 1-2 years lasting pre-dementia phase until development
of dementia, which can be categorized into 3 states (mild, medium, severe) [22, 23].
The progressive cognitive deficits hereby parallel neuropathological changes in the brain,
whereby cognitive deficits vary individually. The degree of disease severeness refers to
cognition and life skills, whereby transition of states can merge. A mild dementia is considered
when complex tasks cannot be performed anymore, but an independent life organisation is
still possible. A medium-state dementia is referred to if an independent life organisation is
impaired but possible with help and observation of family and care-givers. In severe dementia
constant guidance and help is required, an independent life organisation is not possible
anymore.
At early stages of AD deficits are predominantly characterized by impairment of declarative
memory, visual-spatial orientation and lexical-semantic language. Emotionally, in social
contacts as well as in personality, patients with AD appear normal for a long period of time
(“facade”). They tend to trivialize their deficits. When they recognize cognitive dysfunction,
AD patients often describe themselves to be more forgetful without further specification.
Memory impairment (representative brain areas: hippocampus, gyrus parahippocampalis and
adjusted temporomedial areas) affects the ability to encode and recapitulate novel memory
contents for a longer period of time, whereas the short time memory and the working memory
are mostly unaffected in early stages. The procedural memory often keeps unaffected. In the
clinical setting progressive memory deficits often appear in forgetfulness of novel information,
in repetitive phrases, difficulties in maintaining complex tasks (strands), e.g. forgetting where
the keys/money have been stored, which can lead to paranoid reactions. Neuropsychological
characterisations are a slow learning curve, rapid forgetfulness, recency-effects due to deficits
in encoding, impaired and prolonged memorising, intrusions and a reduced discrimination-
ability, non-profit of context cues as well as deficits in orientation in time [22].
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In further disease progression according to a time-associated gradient (first in- last out) also
long term memories (semantic and biographical memory) are impaired, with affection of
identity and personality in medium and severe AD stages [23].
Deficits of the visual-spatial orientation (representative brain areas: parietal lobes) are often
associates with important all-day activities: writing, calculating, reading the clock, getting
dressed or basic orientation in space. This can overlap with memory deficits and deficits in
planning skills. Firstly affected are untrained complex skills, e.g., drawing, clock drawing
(mispositioning of the minute hand, confusion of hour/minute hand), reading street maps,
orientation in unknown buildings, filling in documents. Drawings can show simplifications,
repetitions, altered angles, “closing-in” and loss of perspective. Well established and trained
skills, e.g., reading, signing a paper, getting dressed, are mainly affected in medium disease
stage. A sensitive parameter that can be valuable in early AD diagnosis but also as a parameter
of disease progression is clock reading as a trained skill [24, 25].
Deficits in visual-spatial orientation with massive impairment in complex visual awareness
are the main characteristic  and leading symptom of  the posterior  cortical  atrophy  (affected
brain  region:  atrophy  of  the  parietal  and  occipital  lobe).  The  posterior  cortical  atro‐
phy is  a  recognised variant  of  AD with early  onset,  early  visual  agnosia  and prosopag‐
nosia, whereas memory is less impaired in the beginning [23].  Depending on the affected
projection  system (occipital-parietal  or  occipital-temporal)  problems  of  analysing  visual-
spatial  information:  e.g.,  space,  depth,  movement,  position and orientation (dorsal  visual
route/“where-system”)  or  problems  in  analysing  of  shapes/structures,  colours,  objects,
faces  and  complex  space-topographical  scenes  (ventral  visual  route/“what  system”)  can
occur.  Both  systems  are  tightly  connected  [26,  27].
Affection of language (affected brain region: Wernicke area) is characterized by initial difficul‐
ties in finding the right words, which is compensated by strategies of avoidance and para‐
phrases as well as by difficulties in naming of less frequently used objects. The patients tend
to make semantic-superior and semantic-associative mistakes (dog=animal, pyramid=Egypt
or also volcano=vesuvius). Syntax, articulation and prosody are unaffected.
Material that they read is less often understood, the understanding of complex facts or contents
in the figurative sense (collocations) is declining. Verbal fluency is reduced, whereas the
semantic is more affected than the phonematic [28]. During disease, language becomes
progressively poor of content, stays however relatively fluent with difficulties in word finding
as well as with imprecise, diffuse and less informative comments, drifting from topic, talking
cross purposes and setting phrases. This results in abrupt sentences, mistakes of syntax,
phonematic paraphrases and in problems of speech comprehension for simple comments. In
the final stages a total loss of speech occurs [23].
Next to the 3 main symptoms, disturbances in executive function (affected brain region:
prefrontal cortex) appear. Executive functions comprise: problem solving thinking, monitor‐
ing, planning and conducting of complex tasks, working memory, cognitive fluidity and
flexibility. Besides a reduced word fluidity and flexibility also abilities in planning can be
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impaired early. Especially the so-called set-shifting abilities, that require a permanent shift in
alertness, are affected at early stages [29].
Attention is tightly associated with executive function. This is especially required in complex
tasks. Deficits in attention initially present very discretely, e.g. in dual task-questions (pre‐
frontal cortex, anterior cingulum).
During disease progression, also alertness is impaired which presence of a more rapid
exhaustion.
During medium stages all components of attention are majorly affected [22]. Last but not least,
apraxia (affected brain region: parietal lobe) and agnosia (affected brain region: occipital lobe
and both basal temporal neocortex) can occur already during early and middle stages of
dementia. Simple movements are not possible any longer, inaccurate moves cannot be
corrected, this can present as, e.g., body-part-as object-mistakes (ideomotoric apraxia),
impairment of planning and conducting of sequential tasks (ideatoric apraxia), recognition of
line drawing is inhibited.
Cognitive-related impairment of all-day activities affects complex instrumental skills in early
stages of dementia, e.g. using new instruments, filling in written documents, later on using
familiar devices and basal all-day abilities deteriorate progressively.
Psychiatric side symptoms such as anxiety, agitation, excitability, aggressive behaviour or
paranoia are not frequently present in early stages, but appear more often in middle and late
stages of disease. There is a higher vulnerability for states of disorientation already in the
preclinical stage, e.g. after hospital admissions, drug intolerance, malnutrition. Also depres‐
sive mood changes as well as reduction of daily activities are considered early signs [23].
Depression is the most frequent psychiatric side symptom and accounts for about 30% of the
patients, especially during early disease stage and here from the degree of presentation rather
mild. However, depression is considered a main psychiatric disease in the elderly. In general,
depressed patients can articulate their symptoms more precisely; they can manage their all-
day activities in a better way and demonstrate during neuropsychological testing self-doubts
and complain about deficits in concentration. The mood is continuously suppressed and a lack
of motivation is more exhibited.
The onset of cognitive deterioration is more distinct in patients with depression, whereas in
patients with AD this occurs more gradually. The deficits can affect the whole spectrum of
cognition, whereby executive dysfunction (predominantly flexibility) and problems with
attention dominate. However, also memory deficits are described [30]. In detailed observation
of single tasks aspects, e.g. in recalls of wordlists, primacy more than recency effects are shown,
and recall is generally better.
While demented patients guess more often and describe things, depressed patients react with
omissions and hesitant answers. Orientation is widely intact and confabulation, aphasic and
apractic elements don‘t occur [22, 31].
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3.2. The neuropsychological examination
Major tasks and aims of a neuropsychological examination comprise 1) determination and
quantification of impaired cognitive function and resources as well as their consequences for
maintaining all-day life, 2) assessment on changes of cognitive dysfunctions in progressive or
reversible disease conditions, 3) differential diagnosis and securing of diagnosis as well as 4)
evaluation of therapeutic benefits.
An important detail of the examination is a thorough interview with exploration of the clinical
history, self-observation and observation of others, orientation, current mood situation
(psychiatric side symptoms), as well as observation of behaviour during both interview and
test situation. A final judgement is built from the test results with reference to emotional and
motivational processes, a qualitative mistake analysis, and observation of behaviour during
tests and interview, the resulting information derived from the interview and an evaluation
of all-day competences during course of disease.
Neuropsychological testing represents an essential diagnostic tool in dementia diagnosis. It
should be thoroughly performed and comprise the essential key competences. An “overtest‐
ing” should be avoided. In general, the choice of tests should orientate according to the
individual differential diagnosis that is being questioned, the capacity of the individual patient
and the time that is available.
Consecutively, a choice of test procedures is presented, that have been established in dementia
diagnosis. As some of them cannot be administered solely for securing the diagnosis, a
combination of several test procedures should be used.
For assessment of cognitive deficits in AD both screening methods as well as standardized
psychometric tests are applied. Presumably, the most practical screening test in the clinical
setting is the MMSE (Mini-Mental-State-Examination) according to Folstein et al. [32]. It
comprises the examination of orientation in time and space, retentiveness and memory,
attention and working memory, language (reading, writing, naming, speech comprehension,
reading and meaning comprehension) as well as visual-spatial competences. The test takes
usually approximately 10-12 minutes, the analysis results from a simple summation of points.
At maximum 30 points can be achieved. The specificity ranges at 87 percent and the sensitivity
at 82 percent [33]. However screening tests- as the mentioned MMSE- are only suitable, using
cut off levels, for overviewing and determining severity of the dementia and for follow-up
during disease course.
The MMSE is not acceptably sensitive in early onset dementia and does not allow, amongst
other due to missing age and education correction, a satisfactory differentiation between
“healthy” and “ill”. For quantification of disease severity standard values of interpretation are
provided, that can vary easily. Alternatively also CDR (Clinical Dementia Rating) or GDS
(Global Deterioration Scale) can be applied. A general drop in points of around 3 MMSE points
per year substantiates the suspected diagnosis of AD [34].
The DemTect (Dementia Detection Test), likewise a screening test, focuses more precisely on
Alzheimer-specific impairments with its task of word-list learning and delayed recall.
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Furthermore it comprises more tasks on executive functions (working memory, word fluidity
and cognitive flexibility). At maximum 18 points can be obtained. The DemTect is economic
in time (8-12 minutes), it encloses a rough age correction (< 60 / ≥ 60 years) and presents with
a high sensitivity for early stage AD and MCI [35].
After introduction in 1986 in the USA from the Consortium to Establish a Registry for AD, the
newly established CERAD test battery has received great acceptance also in German-speaking
countries. This novel neuropsychiatric testing tool has developed into a standardized dementia
test procedure which aims to decipher cognitive dysfunction typical of AD [34, 36]. Analysed
skills are: semantic fluidity (naming animals), naming of black and white drawings, verbal
compliance and retentiveness (word list), delayed recall and recognition as well as constructive
praxis (to copy something) and figural memory. The test battery also includes the MMSE. The
results of a huge multicentre-validation study performed in German-speaking countries
(n=1100), show that the variables: verbal fluidity, word list, memory, recall of wordlist,
discrimination ability and recall of constructive praxis majorly contributed to the discrimina‐
bility from healthy elderly persons to AD patients with a sensitivity of 87 percent and a
specificity of 98 percent. Severe differences in profiles of AD patients, patients with vascular
dementia and mixed dementia could not be obtained. A better discrimination was attained
between AD patients, patients with depression and mild impairments. Both patients with
depression and MCI ranged between Healthy and AD [36, 37].
To trace better on subcortical dysfunction, since 2005 additional tasks were included that aim
to quantify on cognitive processing speed and flexibility (Trail making test A and B) as well
as phonematic word fluidity tasks (words with initial letter “s”) (CERAD-Plus). The whole test
duration ranges between 30-45 minutes. The raw score are age- and education-matched (school
and professional education) and also gender-matched. They are designated as z-levels as a
measure of deviation to normal. The CERAD-Plus test battery allows a qualitative assessment
on cognitive ability, on evaluation of disease severity and a follow up on repeated testing.
However, at present a parallel test version is not available, thus it is recommended to use an
alternative test for memorising word lists when test intervals are on short-term. In suspicion
of other underlying dementia causes further psychometric tests can be applied.
As an additional screening instrument for calculation of disease severity and for follow-up,
the clock-drawing test is often recommended [38]. Next to visual-spatial abilities the test requires
abilities in planning and semantic memory. The assessment includes, e.g. the integrity of the
clock face, the presence of the clock hands, problems of drawing and conceptual difficulties.
The sensitivity accounts for 90 percent, the specificity ranges at 56 percent. A qualitative
evaluation is reasonable as well as the observation while drawing the clock face. In a qualitative
feature analysis for securing the AD diagnosis in differentiation to patients with depression
and healthy subjects (n=205, patients of a memory clinic) only errors occurred solely in patients
with AD (with exception of one): in disorganised stereograms, only one clock-hand, mixing of
numbers (1-12 with 12-24), mixing of minutes- and clock-hands, false or altered order of
numbers and inability to write numbers [39].
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In mind of the low specificity of the clock drawing test, Schmidtke et al. suggest an additional
clock reading test with respect that it doesn’t require higher executive function. The clock
reading test is culture-, language-, education- and gender-independent, however shows a
slight age-effect. It is easy to use and quickly analysable by a simple point system. Both in AD
and LBD abnormalities are detected early and in comparison to healthy persons the sensitivity
ranges at 82 percent, the specificity at 70 percent [24, 25].
In suspicion of an apractic dysfunction, a corresponding examination is informally possible,
while allowing the patient to mimic easy gestures or mimic using distinct utensils (e.g.
hammer, saw and scissors). As long as the patient is unable to perform the movements
according to verbal request, one should allow him (to exclude problems with language
comprehension) to imitate the demanded movements. For assessment of an ideatoric apraxia
the patient is asked, e.g. to prepare a letter for shipment.
In order to examine all-day competences there are different tests available, e.g. the ADL-/ IADL-
scale (Activities of Daily Living /Instrumental Activities of Daily Living), the Bayer-ADL-scale
(Bayer Activities of Daily Living) or the FAQ (Functional Activities Questionnaire) which
evaluate distinct functions partially very detailed. These tests are completed in general by
relatives or by the interviewer [40-42]. Hereby, the FAQ has proven more sensitive compared
to the IADL (85% to 57%) in the differentiation of “demented” and “normal”. The specificity
ranged at 81 percent [42].
Psychiatric side symptoms, e.g. depression, are assessed early during the neuropsychiatric
interview. As needed additional depression scales can be used, e.g. the Geriatric Depression
scale (GDS) or the Beck Depression Inventar (BDI), that are available also in short profile [43].
The input of depression scales depends on each situation and on the cognitive capacity of the
patient. It should not lead to extend the usual time of the whole neuropsychiatric test situation.
4. Diagnostic imaging methods in AD
4.1. Computerized Tomography (CT)
Computerized Tomography (CT) is helpful in the detection of atrophy as well as other focal
processes in brain and spinal cord, however it is not sufficient to substantiate AD diagnosis.
Based on the low tissue contrast in comparison to magnetic resonance imgaging (MRI), CT
serves well in the diagnostic classification of dementia syndromes. Advantages compared to
MRI include a shorter time of investigation, low costs and a broad distribution [44]. In addition,
CT allows an uncomplicated monitoring of critically ill patients.
With progressing age, brain volume decreases due to dying neurons and decline in water
content. The annual atrophy rate ranges at around 0.24 % of total brain volume and is visible
by the expansion of the ventricular system [45].
In AD, patients show a progressive brain atrophy in advancing disease which lies above the
age matched population. This is demonstrated by enlargement of sulci and a dilatation of the
New Frontiers in Alzheimer's Disease Diagnosis
http://dx.doi.org/10.5772/59652
265
ventricular system. Hereby, the dilatation of the ventricular system points to a subcortical
tissue loss whereas the enlargement of the outer CSF interspaces points to cortical tissue loss
[46]. The senso-motoric and the primary-visual cortex stay unaffected.
4.2. Magnetic Resonance Imaging (MRI)
MRI allows a high-contrast presentation of neuro-anatomical structures, pathological proc‐
esses as well as of functional changes in brain activity. With progressive age a higher exchange
rate of fluids exists between the ventricular system and the brain parenchyma. This is visible
in T2- and Fluid-attenuated inversion recovery (FLAIR)-sequences by signal alterations in the
ependyma of the anterior horns [47]. Intermittent, subcortical and central signal increases in
the white matter (white-matter-lesions) increase with progressive age. Additionally brain iron
accumulation can be detected in basal ganglia by increasing signal changes in T2-sequences.
Already in early AD stages MRI can display brain atrophy patterns. These can predominamtly
be located in the medial temporal lobe, in the hippocampus and the gyrus parahippocampalis.
Also, the entorhinal cortex, the amygdala, basal ganglia as well as thalamus and the parietal
cortex can be involved [44]. An important role in the early detection of AD plays the Nucleus
basalis Meynert. The voxel-based morphometry (VBM) reduces the weaknesses of predomi‐
nantly investigator-dependent manual volumetry [48]. Modern computer techniques allow
the spatial recognition of specific brain regions or the whole brain [49]. Hereby the volume of
the typically affected brain region is exactly displayed and is comparable to that of other control
groups. The majority of published studies show that patients with a MCI present with a smaller
hippocampal volume than healthy controls and patients with AD have a smaller hippocampal
volume in comparison to patients with MCI [50]. Patients with MCI hold an elevated risk for
the development of AD [51]. Typical AD changes can also occur after brain trauma and long-
lasting epilepsy.
Functional MRI (fMRI) has the potential to demonstrate cerebral blood flow as well as oxygen
use of certain brain areas in response to specific stimuli or while processing certain cognitive
tasks.
Due to the inherent magnetic properties of blood, represented by hemoglobin and deoxyhe‐
moglobin, different patterns of activiation are visible [44].
Despite of the high spatial resolution, this method presents with a high sensitivity for minor
head movements. Studies of AD patients show a decrease of activitiy in the hippocampus, the
parahippocampal areas as well as in the parietal and pre-frontal cortex in comparison to
healthy control groups. Furthermore, fMRI is useful in monitoring of medical treatment in AD
patients.
4.3. Emission computed tomography (SPECT and PET)
Imaging via single photon emission computed tomography (SPECT) and positron emission
computed tomography (PET) allows the detection of local hemodynamic and metabolic
dysfunction. After intravenous injection of a radioactive tracer and uptake in brain, the tracer
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localizes at the region of regional acitivity and images are taken. As the tracers often have short
radioactive half life, the radioactive decay (emission of positrons) can be measured.
SPECT imaging shows the regional cerebral blood flow (rCBF) at rest by the regional uptake
of glucose as an expression of neuronal activity. Hereby functional abnormalities can already
be detected before symptom onset. The tracers 99mTc-HMPAO and 99mTc-ECD are mostly used
in clinical practise. Due to their lipophilic character the tracers reach the cells in the first minutes
after injection proportionately to rCBF [52]. The typical SPECT image in AD is characterized
by a reduced rCBF in the medial and superior temporal lobes as well as in the posterior
cingulum and precuneus without a reduced striatal DAT-binding [53]. Due to a very low
spatial resolution of SPECT the diagnostic accuracy is lower than PET [54]. However applica‐
tion can be meaningful in clinical practise in order to differentiate other dementia causes.
PET imaging illustatrates a regional dysfunction of glucose metabolism via application of 18F-
FDG. Patients with AD demonstrate here, according to SPECT, a typical nuclide-distribution
pattern of neuronal loss. Over 85 % of PET diagnosed AD patients could be neuropathologi‐
cally verified [53]. At early AD disease stage and before symptom onset, a temporoparietal
metabolic dysfunction is visible by voxel-based (volumetric pixel) analysis. Also patients with
a genetic risk for development of AD show early decreases in signal activity [55]. As PET is
the most efficient method for diagnostic verification of an AD, it has meanwhile established
to a standard tool in dementia research [56].
For further diagnostic approaches the tracer 11C-PIB was developed, which allows detection
and distribution of Aß-plaques in vivo [57]. Next to an efficient diagnostic procedure and early
disease recognition the dimension of AD dementia can be illustrated.
5. Biomarkers in peripheral tissues
Biomarkers are used as indicators of normal and pathogenic processes in a broad range of
tissues, especially in peripheral tissues, which facilitates the accessibility of testing samples
with minimal invasive methods. Despite substantial progress has been made in the area of
biomarker development to confirm the diagnosis at early-clinical AD stages, less is known
about the potential role of biomarkers in peripheral tissues in the prediction of AD [58]. Since
it has been demonstrated for decades the existence of biochemical changes in the brain
preceding the clinical AD onset (up to 20 years in advance) [59, 60] it is suggested that these
changes may be also indirectly reflected in biological fluids. However, no tests are currently
available to confirm an early AD diagnosis prior to clinical or symptomatic manifestations.
The ongoing standardization efforts and quality control programs in biomarkers analysis, the
development of tests in fully automated instruments, the combined detection of the well-
established core biomarkers, the discovery of new regulated molecules improving current
sensibility and sensitivity and the analysis of novel promising biomarkers in large independent
cohorts will boost biomarker´s performance and facilitate the introduction of new AD
diagnosis and prognosis tests in biological fluids in clinical routine.




CSF is the prime target among biological fluids in the search of specific biomarkers related to
neurological disorders. The easy accessibility to this biofluid and its singular biophysic-
chemical characteristics make CSF ideal for biomarkers investigation. On one hand, CSF is not
a very complex fluid, being composed of a restricted amount of metabolites [61], which
facilitates technical screening for regulated molecules. On the other hand, the direct contact
between CSF and the extracellular space of the brain puts CSF in a valuable position to be
considered as a potential indicator of the pathological processes occurring in the brain during
different disease stages. This last aspect has not been analysed in depth since real comparisons
and correlations are cumbersome and can only be formally made when using CSF and brain
tissues from the same patients and the same disease stages.
The performance of CSF biomarkers as a diagnostic tool has greatly improved in parallel with
the improvement of detection methodologies such as new generation proteomic technologies
and high-throughput transcriptomic methodologies (deep-sequencing, microarrays and
quantitative PCR panels), which eased and expanded the possibilities to measure full expres‐
sion signature in a single assay enabling the inference of networks and biological functions
associated to deregulated datasets. Indeed, current data indicate the existence of deregulated
levels of proteins, peptides, small RNAs, mitochondrial DNA and a broad range of metabolites
in the CSF of AD samples. In addition new outcomes are expected from worldwide undergoing
large longitudinal studies in very-well defined cohorts [62].
5.1.1. Protein biomarkers
In recent years, a number of reports have exploited proteomic techniques to study the levels
of selected proteins and peptides in the CSF of healthy and diseased individuals. Current data
indicate that proteins and peptides such as β-amyloid (Aβ1-42/Aβ42 and Aβ1-40/Aβ40), total
tau and phosphorylated tau (p-tau) meet the criteria to discriminate AD from individuals
suffering from other types of dementias, as well as from healthy individuals and are considered
as the core AD biomarkers [63]. According to different studies these biomarkers meet the
consensus recommendations on AD biomarkers that should have >80% sensitivity and >80%
specificity [64]. Importantly, core AD biomarkers molecules correlate with neuropathological
hallmarks of AD, such as the presence of extracellular amyloid plaques (Aβ peptides), axonal
degeneration (tau protein) and neuronal tangles (p-tau).
Three main observations unveil the clinical relevance of these molecules. Firstly, their appro‐
priate sensibility and sensitivity have been successfully validated by independent large-scale
multicentre studies [65-69], although these studies also point out that biomarkers measure‐
ments present significant inter-laboratory variations [70]. Secondly, Aβ42, tau and p-tau have
been validated as predictors of AD in patients with MCI [71-74]. Lastly, longitudinal studies
indicate that, at least, Tau and Aβ42 in CSF reflect the underlying disease state in early clinical
and late stages of AD.
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5.1.1.1. Aβ peptides
Aβ42 along with Aβ40 is secreted into the extracellular space and biological fluids, including
CSF, as consequence of the proteolytic activity of proteinases on the Amyloid precursor protein
(APP). Both peptides are found in senile plaques but their intracellular production, aggregation
rates and proposed pathogenic functions are significantly distinct [75-77].
A consistent decrease in Aβ42 levels has been observed in the CSF of patients suffering from
AD in several studies [78-80] but also in Subcortical White-matter Dementia (SWD) [81] and
in Down Syndrome (DS) [82]. Reduced Aβ42 levels in AD are suggested to reflect either
sequestration of Aβ42 in senile plaques, since Aβ42 CSF levels inversely correlate with the
presence of senile plaques [83], or due to non-detectable Aβ42 oligomers in the assay, although
alternative explanations may be plausible. In FTD, Aβ42 levels are significantly lower than in
control samples, but higher than in AD cases [81, 84]. Aβ42 sensitivity and specificity in AD
samples ranges from 78 to 100% (mean 85,6%) and from 67 to 100% (mean 88,5%), respectively
[78]. A recent meta-analysis of 50 analytical studies indicates that CSF Aβ42 concentrations are
significantly lower in AD when compared to MCI, FTD, PD and VaD but only moderately
lower when compared to LBD [85].
Contrary to what is observed with Aβ42, Aβ40 and Aβ38 levels are not altered in the CSF of
AD patients [79, 86, 87], but a significant decrease in Aβ40 levels is observed in FTLD when
compared to AD and control cases [88]. In addition, Aβ40 levels, and more markedly Aβ38
levels, are decreased in FTD when compared to control samples [89].
A growing body of evidence suggests the superior performance of Aβ42/Aβ40 ratio when
compared to Aβ42 alone using different analytic assays [79, 90, 91]. Importantly Aβ42/Aβ40
ratio is able to predict the conversion from MCI patients to AD when compared to cognitively
stable MCI patients and MCI patients who developed other forms of dementia [79]. Aβ42/Aβ40
ratio is also able to discriminate better AD from VaD, LBD and non-AD dementia than Aβ42
alone and equally AD from FTD and non-AD dementia than the combination of Aβ42, p-tau
and total tau [92]. Multiple studies also show an increased sensitivity and specificity in the use
of Aβ ratio when compared to Aβ42/tau ratio, although the performance of combined
biomarker analysis in AD diagnosis and prognosis is still a matter under discussion [93-96].
In addition to the regulated levels of monomeric Aβ species in the CSF of AD patients,
encouraging observations have been reported in the potential diagnostic and prognostic role
of BACE1, one of the main enzymes involved in the pathological cleave of the APP. Several
independent observations indicate the presence of higher BACE1 levels and activity in the CSF
of MCI and AD samples when compared to controls [97-100]. BACE1 activity is also increased
in CJD samples [101] suggesting common pathological mechanisms among both diseases.
Importantly, BACE1 correlate with classical AD biomarker’s profile, brain atrophy in AD cases
[102] and ApoE4 genotype [99], the latter being associated with an increased Aβ peptide ex
vivo production [103]. In addition, specific BACE1 inhibitors dramatically reduce the presence
of Aβ peptides in the CSF of AD patients [104] pointing out for a direct correlation between
brain Aβ peptide processing and Aβ CSF levels.




Recent studies demonstrated the presence of increased levels of Aβ oligomeric species in the
CSF of AD patients when compared to controls using a broad range of methodological
approaches [105-110]. Indeed, the analysis of individual Aβ oligomeric species is gaining
experimental momentum due to their potential specific role in AD pathogenesis. Aβ40
oligomers levels are found to be increased in the CSF of AD patients at different disease severity
stages, and a combined analysis of Aβ40 oligomers and monomeric Aβ42 greatly improved
sensitivity and specificity to 95% and 90%, respectively [108]. Although the pathogenic role of
Aβ40 in AD is still under discussion Aβ40 deposits have been reported both in control and AD
brains [111, 112]. Aβ40-positive senile plaques with amyloid core are frequently associated
with microglia in contrast to Aβ42-positive plaques [111], suggesting a role of microglia in the
generation and aggregation of Aβ40 species in diseased brain. However, the different ability
of Aβ fibrils and oligomers to react with microglia suggests a more complex scenario [113].
Aβ42 oligomers are increased in the CSF of AD patients [114] and the ratio of Aβ oligomers to
Aβ42 is significantly elevated in AD patients [115]. Interestingly, the increased levels of Aβ42
oligomers in the CSF of MCI and AD samples may explain decreased levels of monomeric
Aβ42. The recent development of the protein misfolding cyclic amplification assay (PMCA),
based on the seeding activity of Aβ oligomers catalysing the polymerization of the monomeric
Aβ, permits the discrimination of AD samples from other neurodegenerative non-degenera‐
tive neurological diseases with a sensitivity of 90% and specificity of 92% [109]. The use of Aβ-
PMCA as a prognostic tool for detection of MCI still needs to be established. Importantly,
detection of Aβ oligomers in the CSF is highly dependent on the native or disaggregated state
of these oligomers [114, 116].
The finding that regulated levels of Aβ oligomer species are present in the CSF of AD patients’
biofluids has a tremendous translational interest, since growing evidences indicate that soluble
Aβ oligomers rather than aggregated Aβ plaques are more likely to be the main pathogenic
agents of disease [117-119]. Consequently, preliminary data indicate that the analysis of Aβ
oligomers, combined with levels of soluble Aβ peptides, may be relevant disease predictors
and valuable tools for the analysis of AD progression.
5.1.1.3. Tau
The levels of total tau in the CSF, contrary to Aβ42 levels, increase with age [120]. Increments
in tau levels have also been described in the CSF of AD and MCI patients in a broad range of
several studies [121, 122] ranging from moderate to severe depending on the methodology and
cohort used [78]. It is believed that deregulated tau may be reflecting the neuronal and axonal
damage present in brain tissue and, as a consequence, the presence of increased tau levels is
not a specific event for AD. Accordingly, transient tau increments have been also reported in
acute stroke [123], and the most increased tau levels are observed in prion diseases such as in
CJD, where massive neuronal cell death is present [124, 125]. Higher CSF tau is also associated
with smaller brain volume in individuals with AD [126]. On the other hand, neurological
diseases with minor neuronal loss and other dementias such as VaD, LBD and alcoholic
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dementia reflect minor or no significant changes in the levels of tau protein in the CSF, and
tauopathies such as FTD also present inconsistent data [121, 127, 128].
A meta-analysis from different studies comparing tau levels in different dementia samples
found that, although tau levels in AD are significantly increased when compared to controls,
tau concentrations are moderately elevated in LBD, FTLD and VaD impeding a clear stratifi‐
cation between disease groups. Nevertheless, tau levels are useful to differentiate VaD from
stroke [129] and, as expected, only CJD is characterized by extremely increased tau values,
resulting in a sensitivity and specificity over 90% [130].
The improved performance of tau when analysed together with other AD biomarkers has
been widely demonstrated [131,  132].  The combined use of  Aβ42 and tau discriminates
better between controls and AD and is very useful to predict MCI progression [69, 133].
A  recent  study  also  showed  that  decreased  Aβ42  and  increased  tau  levels  are  able  to
discriminate  LBD from PD patients  in  spite  of  both  being synucleopathies  [134].  In  the
same line of  evidences,  combination of α-synuclein levels and Aβ42/tau ratios improves
the diagnostic accuracy of PD [135].
A broad range of studies also demonstrated the helpfulness of the combined analysis of tau
with non-AD core biomarkers. Assessment of tau and neuronal thread protein raises specificity
and sensitivity for AD when compared to the individual analysis of both proteins [136].
Similarly, integrated analysis of tau and the regional cerebral blood flow in the posterior
cingulate cortex discriminates MCI progressing to AD from non-progressive MCI [137]. The
combined analysis of tau is also valuable for discriminating other diseases besides AD. As an
example, the merged analysis of tau and midbrain-to-pons atrophy is reported to be useful for
early identification of progressive supranuclear palsy (PSP), discriminating PSP cases from
controls and patients suffering from corticobasal syndrome (CBS) and FTD [138].
5.1.1.4. Phospho-tau
Similarly to total tau, p-tau levels are increased in AD samples, although higher variability on
its specificity and sensibility is reported when compared to the non-phosphorylated tau form
[78, 127]. Several considerations should be done in this regard.
On one hand, the number of studies analysing p-tau levels is not as large as those performed
for its non-phosphorylated form. In addition, sensitivity and sensibility may depend on the
analysed phosphorylation site, although sensitivity for AD seems equal for at least the three
main epitopes used in clinical diagnosis [139]. Importantly, results from a meta-analysis study
indicate that tau phosphorylated at the Threonine 181 levels are able to discriminate AD from
other dementias and MCI [140].
On the other hand, the utility of p-tau in the differential AD diagnosis against other neurode‐
generative diseases is advantageous over total tau since p-tau levels reflect AD pathogenesis
[141]. Indeed, p-tau levels in the CSF may reflect the levels of tau phosphorylation in AD brains.
Tau is more increased in the CSF of sCJD patients than in AD, while p-tau is only modestly
increased in sCJD [142]. In addition, tau levels are increased in neurological diseases such as
in acute ischemic stroke, while p-tau levels remains unaltered [123]. Indeed, tau phosphory‐
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lation is physiologically regulated during several biological processes such as neuronal
development, while tau levels usually remain more stable. Therefore, a direct correlation
between total tau and p-tau levels cannot be established, and several lines of evidence indicate
that p-tau levels are differently regulated, not only in AD, but also in other neurodegenerative
diseases. In this regard, the main tau kinase, Glycogen synthase kinase 3 (GSK3) is assumed
to be hyperactivated in AD brain, inducing pathogenic tau hyperphosphorylation, aggregation
and formation of the intracellular NFTs. Although a direct correlation between GSK3 activity
and tangle formation in AD is still under discussion [143], GSK3 levels and activity are
markedly reduced in sCJD brain [144]. Thus, the distinct regulation of tau phosphorylation in
the brain of AD and CJD, may explain the different p-tau/tau ratios observed in both diseases,
which permits a differential diagnosis [145].
Recently it has been observed that patients suffering from rpAD present highly increased p-
tau levels in the CSF [146] when compared to controls and classical AD patients. Since it is
estimated that rpAD may be accounting for 10-30% of all AD cases, it is urgently needed to
establish if lack of disease stratification may lead to misinterpretation of p-tau analysis between
rapidly progressive and classical AD forms. In this regard, a combination of high CSF tau
without proportionally elevated p-tau-181 is associated with a faster rate of cognitive decline
[147]. In this regard, longitudinal studies indicates that a combination of low Aβ42 and high
tau and p-tau levels is highly predictive of MCI progression and cognitive decline rate [74, 148].
5.1.1.5. Inflammatory cytokines
A common feature in the Central Nervous System of neurodegenerative diseases is the
presence of chronic neuroinflammation associated with an exacerbated gliosis [149]. The role
of a chronic and sustained inflammation in neurodegeneration is still a matter of debate as
neuroinflammation has been suggested to play both detrimental and protective functions
depending on disease stage, brain region, activation of anti-inflammatory mechanisms and
cellular milieu among others [150]. Besides these considerations point out a critical role of
neuroinflammation in the molecular mechanisms linked to AD pathology [151] and a broad
range of inflammatory cytokines and immune response mediators are increased in the CSF of
AD patients. A correlation between inflammatory markers and biomarkers of neurodegener‐
ation has been described [152], and consequently, neurodegenerative disorders with high
inflammatory chronic profiles such as prion diseases [153] present higher inflammatory-
related deregulations in the CSF [154, 155]. However, the specific inflammatory profile
observed in different types of dementia and at different disease stages indicates that inflam‐
matory biomarkers could be used as surrogate markers for AD diagnosis and prognosis.
The anti-inflammatory cytokine TGFβ–1 is consistently upregulated in AD cases [156, 157].
Interestingly, during the progression from MCI to AD, a pro-inflammatory state is proposed
since MCI patients who progressed to AD showed higher TNFα and lower TGFβ–1 and Aβ42
levels than control individuals or those non progressing to AD [158]. These data are in
agreement with increased levels of the acute-phase C-reactive protein (CRP) and IL-6 in the
CSF of MCI patients when compared to AD patients, indicating that inflammatory mechanisms
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are already progressing even before changes in core AD biomarkers such as Aβ42 and tau can
be detected in the CSF [159].
In relation to this, a comparative analysis between Amnestic Mild Cognitive Impairment
(aMCI) and MS patients indicated that pro-inflammatory cytokines and CD45+ lymphocytes
are present in the same levels in both diseases. Taking into account that MS can be considered
the most representative neuroinflammatory disease, these observations indicate that inflam‐
matory mechanisms may be crucial for AD etiopathology.
In  this  regard,  the  pro-inflammatory  cytokine  osteopontin  (OPN),  also  known  as  the
secreted  phosphoprotein  1  (SPP1)  and  involved  in  macrophage  recruitment  to  inflam‐
matory  sites  and  cytokine  production  [160],  is  also  elevated  in  the  CSF  of  AD  pa‐
tients  and in  MCI  patients  developing  AD.  OPN levels  correlate  with  cognitive  decline
and with  increased  levels  in  early  disease  phases  [161,  162].  OPN has  also  been  found
elevated  in  the  CSF  during  attacks  of  MS  [163].
In addition, the major acute-phase protein SAP (Serum amyloid P component) has lower levels
in MCI patients who progressed to AD than in those who did not progress to AD [164],
suggesting that low SAP levels are linked to an increased risk of progression to AD.
Alternative promising inflammatory-biomarkers have been proposed. On one hand, lipocalin
2, whose levels are decreased in the CSF of MCI and AD patients and increased in brain regions
with associated AD pathology [165]. On the other hand, the astrocytic marker YKL-40, has
been reported to be increased in AD at early stages of the disease [166-169] and in FTD and
aMCI patients [166]. In addition YKL-40 levels correlate positively with the classical core
biomarkers tau and p-tau [166].
5.1.1.6. MicroRNAs
microRNAs (miRNA) are endogenous small non-coding RNAs (20-22 nucleotides) that are
involved in post-transcriptional gene regulation by targeting mRNAs for cleavage or transla‐
tional repression [170]. miRNAs have emerged as key regulators of various aspects of neuronal
development and dysfunction. Deregulated small RNA signatures, especially miRNAs, have
been observed in the brain of a broad range of neurodegenerative diseases such as AD, PD,
HD or ALS [171, 172] and experimental evidences ascribe a functional role to miRNAs in the
pathogenic molecular mechanisms leading to neurodegeneration [173-175]. With the advent
of high-throughput technologies, full transcriptomic signatures can be provided not only from
tissues, but also from samples with small amounts of starting material such as biological fluids
and associated exosomes [176-178]. In this regard, more than 100 circulating miRNAs are
deregulated in pathological conditions [179] and some of them have been proposed as potential
biomarkers for disease diagnosis and prognosis, mainly in cancer and neurodegenerative
diseases. Regarding the levels of circulating miRNAs in AD, several studies already reported
changes when compared to control samples. A recent pilot study in two different cohorts
showed that hsa-miR-27a-3p expression is reduced in the CSF of AD patients [180]. Decreased
levels of this miRNA correlate with high tau and low Aβ amyloid levels. A second study
analysed a selected group of miRNA candidates and observed that miRNAs 34a, 125b and
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146a levels were significantly lower in the CSF of AD patients when compared to control cases,
while the levels of the miRNAs 29a and 29b were significantly higher [181]. In an independent
study low levels of miRNA-146a were also detected in the CSF of AD patients [182]. In this
regard the expression of miRNA-146a is increased in AD [183] and CJD brains [184], in AD
mice models [185] and in scrapie mice [184]. miRNA-146a expression in AD mice models also
correlates with senile plaque density and synaptic pathology [185]. This miRNA is induced by
the interleukin IL-1β, modulating the expression of IL-6 and the cyclooxygenase COX-2 and
acting as a negative regulator of the astrocyte-mediated inflammatory response [186, 187]. In
addition miRNA-146a negatively regulates TLR signalling to prevent exacerbated inflamma‐
tion, thus, it seems to play a key role in the modulation of the neuropathology associated to
chronic inflammation in neurodegenerative diseases. Whether the regulation of miRNAs in
CSF is a consequence of neuronal cell damage or a modulated pathogenic response is still a
matter of discussion.
In summary, all preliminary studies argue for the presence of deregulated levels of miRNAs
in the CSF of AD patients with potential translational value. Exclusion of blood contamination
effects, standardization of the assays, together with cross-disease and technical validation in
larger cohorts need to be carried out to assess the potential role of miRNAs signatures as
specific diagnostic and prognosis biomarker tool in AD and to define new diagnostic thera‐
peutic opportunities related to the miRNA field.
5.1.1.7. Mitochondrial DNA
A pioneering study demonstrated that asymptomatic patients at risk of AD and symptomatic
AD patients exhibit a significant decrease in the levels of circulating cell-free mtDNA in the
CSF [188]. Data were generated by qPCR and digital droplet PCR and validated in an inde‐
pendent cohort of patients. Interestingly, this decrease is disease-specific, as mtDNA levels in
the CSF of FTLD patients remain unchanged. Since decreased levels of mtDNA precede the
appearance of the classical AD biomarkers such as Aβ42, mtDNA is an excellent potential pre-
clinical AD biomarker. Further studies in larger cohorts including rpAD and CJD samples will
determinate the clinical use of mtDNA analysis as a prognosis AD biomarker.
5.1.1.8. Metabolic profile
The use of analytic technologies such as Nuclear magnetic resonance and Liquid chromatog‐
raphy–mass spectrometry to analyse the metabolic signatures of biological fluids deserves
special attention [189]. The metabolic profile in human CSF samples of AD patients and age-
matched healthy controls unveils the presence of a significant presence of deregulated
metabolites in AD cases [190]. Among them, higher corticols levels are found in AD cases,
which correlate with AD progression and severity. In addition, the same study proved that
combined analysis of different metabolites may increase sensitivity and specificity above 80%.
A second metabolic profile study identified the deregulated metabolic pathways in the CSF of
MCI and AD patients [191]. The number of altered pathways increased with disease severity.
Among them, Krebs cycle was significantly affected in MCI and cholesterol and sphingolipids
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transport was altered in AD. A high percentage of altered pathways in the CSF were also
deregulated in plasma from the same individuals (30% in MCI and 60% in AD, respectively).
Deregulated pathways performing the best disease discrimination were biosynthesis and
metabolism of cortisone and prostaglandin 2.
Finally, a third study using metabolomics in the CSF of MCI and AD patients demonstrated
the presence of elevated methionine (MET), 5-hydroxyindoleacetic acid (5-HIAA), vanillyl‐
mandelic acid, xanthosine and glutathione levels in AD patients and elevated 5-HIAA, MET,
hypoxanthine and other metabolites in MCI patients when compared to healthy controls.
Metabolite ratios revealed changes within tryptophan, MET and purine pathways [192],
showing a partial overlap between MCI and AD.
Metabolomics is a promising tool for AD diagnosis indicating a slightly lower or similar
performance when compared to classical AD biomarkers such as tau and Aβ42 depending on
the study. Further analysis in large independent cohorts, technical updates as well as a
combination of metabolic profiling with classical or alternative biomarkers will define the
potential use of high throughput metabolic analysis in the AD diagnostic field. Besides,
metabolite signatures may help to unveil the progression mechanisms and pathways leading
to different dementia stages.
5.2. Blood
Despite the description of altered levels of several molecules in the blood levels of several
molecules in the blood of AD patients as AD clinical biomarkers. Direct analysis in blood or
blood-derived serum or plasma samples presents a broad range of advantages over CSF
analysis. Blood extraction is minimally invasive and sample is easily collected, processed and
stored over time. However, variations in the levels of blood metabolites may be reflecting a
broad spectrum of changes not directly related to the neurodegenerative process. In addition,
the dynamic range of the changes are lower than in CSF obtaining, most of the times, incon‐
sistent data. Additionally, contrary to CSF, blood is a very complex fluid composed of different
types of metabolites and cell types that present significant oscillations in response to external
factors not related to pathogenic events. The analysis of specific blood cells could be an
alternative approach to link potential biomarkers levels with AD pathology, being a field under
intense study.
5.2.1. Protein biomarkers
The core CSF AD biomarkers present minimal alterations in plasma. Aβ40 levels are higher in
AD than in controls, although a high overlap is observed between groups. No changes have
been observed for Aβ42, and Aβ40 and both Aβ40 and Aβ42 levels showed no association with
cognitive decline [86]. Albeit some partial overlap between groups, tau levels in plasma are
increased in AD when compared to control and MCI patients. Interestingly, tau levels cannot
differentiate non-progressive from AD progressive MCI patients and there is a lack of
correlation between CSF and plasma tau levels [193].
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High-throughputs proteomic studies have tried to report the complex deregulated signatures
between control and AD samples. A 2D-Mass spectrometry-based study detected a deregu‐
lated set of proteins in AD plasma complement factor H precursor and α-2-macroglobulin,
which were validated and correlated with disease severity [194]. Independent multi-analyte
profiling studies also demonstrated the presence of deregulated levels of proteins in MCI and
AD samples when compared to controls both in serum and plasma. Among them some hits
are related to AD pathogenesis such as the apoE [195, 196] as well as a broad range of inflam‐
matory mediators [196, 197]. In an array-based ELISA study, 18 signalling proteins were able
to distinguish AD from control samples with high accuracy (90%) and to predict MCI to AD
progression [198], although the validation of this dataset has been ambiguous [199, 200]. The
observation of a high variability between independent analyses indicates that further valida‐
tions by independent methodologies in different cohorts need to be performed before resolving
the clinical relevance of high-throughput blood-based analysis.
Alternative plasma biomarkers include the brain-reactive autoantibodies, present in sera
irrespective of the presence of any pathology. This finding led to the analysis of the potential
AD-specific autoantibody signature, which has been suggested to possess diagnostic value
due to its ability to distinguish AD cases from controls, PD and breast cancer samples [201].
5.2.2. microRNAs
miRNA signature from CSF is only slightly more stable when compared to serum, suggesting
that both biofluids are appropriate for the screening analysis of small RNAs [202]. Therefore,
several studies addressed the potential deregulated miRNA signature in blood-derived AD
samples. Using a microarray and qPCR validation approach the miR-125b, miR-23a and
miR-26b were downregulated in the serum of AD cases when compared to non-inflammatory
and inflammatory neurological controls and to FTD cases [203]. miR-125b presented the best
accuracy discriminating AD from other groups. The same study observed that miR-125b and
miR-26b levels were also diminished in the CSF of AD patients. An independent validation
study was able to replicate downregulation of miR-125b in AD serum [204].
In a different approach, using RNA-sequencing and qPCR validation, downregulated levels
of the miR-98-5p, miR-885-5p, miR-483-3p, miR-342-3p, miR-191-5p and let-7d-5p in the serum
of AD cases were reported. The miR-342-3p showed the best sensitivity and specificity and
correlated with cognitive decline [205]. However, downregulated levels of miR-342-3p in
biological fluids are also a common hallmark in cancer [206]. Using a similar approach a 12
blood-based miRNA signatures was suggested to discriminate AD patients from controls and
samples from patients suffering from different neurodegenerative diseases with high diag‐
nostic accuracies [207]. Nonetheless, the different sample origin impedes a formal comparison
between disease group’s studies. The analysis of peripheral blood mononuclear cells identified
upregulated levels of miR-34a, miR-181b in AD cells [208].
Despite the promising future of miRNA as biomarkers tools of clinical relevance, several
considerations needs to be done. Lack of validation among current available studies, even
when using similar platform, indicates that sample collection and methodology needs further
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standardization. In addition, high-throughput data need to be cross-validated in longitudinal
studies using different cohorts and selected miRNAs validated in multicentre studies. Under
these conditions miRNA in blood-related samples may serve as prognostic and diagnostic
through the analysis of miRNA signatures alone or combined with the analysis of classical AD
biomarkers.
6. Conclusion
The use of combined analysis of current AD diagnostic tools is gaining experimental momen‐
tum due to its demonstrated value as a better prognostic and diagnostic tool when compared
to individual assessments. As most promising candidates, CSF markers as well as methods of
in vivo neuroimaging have been identified. Among them, we can find structural MRI, 18F-FDG-
PET and novel in vivo amyloid-PET imaging [209, 210]. In longitudinal studies it was shown
that with the help of these biomarkers AD could be diagnosed already in mild symptomatic
states with high accuray allowing a predictability of its development [210]. Investigations of
patients with genetic AD have demonstrated already 15 years prior to the onset of dementia
significant pathological alterations in distinct biomarkers [211, 212].
Although these results are only assignable in a limited way to sporadic AD, the latter study
provides impressive evidence on the long preclinical course of AD.
Current  diagnostic  concepts  should therefore  apply  not  at  first  when AD dementia  has
developed,  but  support  explicitly  the application of  biomarkers at  distinct  stages of  AD
as it  was  shown that  biomarkers  become positive  already at  early  and presymptomatic
stages [213, 214].
In conclusion, differential diagnosis of a dementia syndrom requires esides clinical history and
neuropsychological testing, analysis of metabolites in biological fluids as well as imaging
methods. All these diagnostic approaches will not only allow an explanation towards the
underlying cause of dementia but will also be useful in monitoring disease treatment and
progression. The detection of AD at an early stage is hereby essential, as a further disease
progression can be influenced positively by early initiation of treatment.
Integration of data generated during the last decades should be used to build up a worldwide
rational algorithm based in the use of standardized, economically affordable methodologies
and easily accessible samples.
Nomenclature
AD: Alzheimer’s disease, rpAD: rapidly progressive Alzheimer’s disease, CJD: Creutzfeldt-
Jakob disease, aMCI: Amnestic Mild Cognitive Impairment, MCI: Mild cognitive impairment,
FTLD: Frontotemporal Lobe Degeneration, FTD: Frontotemporal Dementia, CSF: Cerebrospi‐
nal Fluid, PD: Parkinson Disease, HD: Huntington Disease, ELISA: Enzyme-Linked Immuno‐
Sorbent Assay, MS: Multiple Sclerosis, SWD: Subcortical White-matter Dementia, MMSE:
Mini–mental state examination, APP: Amyloid precursor protein, DS: Down Syndrome, CRP:
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C-reactive protein, PSP: progressive supranuclear palsy, CBS: corticobasal syndrome;
NINCDS/ADRDA: American National Institute of Neurological and Communicative Disor‐
ders and Stroke /Alzheimer’s disease and Related Disorders Association; DGPPN: German
Society of Psychiatry, Psychotherapy and Neurology; DGN: German Neurological Society;
MRI: Magnetic Resonance Imaging, PET: Emission Computed Tomography; SPECT: single
photon emission computed tomography; EEG: Electroencephalogram; CT; Computerized
Tomography; CDR: Clinical Dementia Rating; GDS: Global Deterioration Scale; ADL-/IADL:
Activities of Daily Living /Instrumental Activities of Daily Living; VBM: voxel-based morph‐
ometry; FLAIR; Fluid-attenuated inversion recovery; rCBF: regional cerebral blood flow.
Acknowledgements
The study was supported by the EU grants JPND-DEMTEST (Biomarker based diagnosis of
rapid progressive dementias-optimization of diagnostic protocols, 01ED1201A) and PRIORI‐
TY (Protecting the food chain from prions, FP7-KBBE-2007-2A) and by funds from the Federal
Ministry of Health (grant no. 1369-341] and from the German Center for Neurodegenerative
Diseases (DZNE).
Author details
Franc Llorens1,2, Sabine Nuhn1, Christoph Peter1, Inga Zerr1,2 and Katharina Stoeck1
1 Department of Neurology, Clinical Dementia Center, University Medical School, Georg-
August University, Göttingen, Germany
2 German Center for Neurodegenerative Diseases (DZNE) – Göttingen, Germany
References
[1] Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA. Alzheimer disease in the
US population: prevalence estimates using the 2000 census. Arch Neurol 2003 Aug;
60:1119-1122.
[2] Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global
burden of Alzheimer's disease. Alzheimers Dement 2007 Jul;3:186-191.
[3] Boise L, Neal MB, Kaye J. Dementia assessment in primary care: results from a study
in three managed care systems. J Gerontol A Biol Sci Med Sci 2004 Jun;59:M621-M626.
Alzheimer's Disease - Challenges for the Future278
[4] Boustani M, Peterson B, Hanson L, Harris R, Lohr KN. Screening for dementia in pri‐
mary care: a summary of the evidence for the U.S. Preventive Services Task Force.
Ann Intern Med 2003 Jun 3;138:927-937.
[5] Gaugler JE, Ascher-Svanum H, Roth DL, Fafowora T, Siderowf A, Beach TG. Charac‐
teristics of patients misdiagnosed with Alzheimer's disease and their medication use:
an analysis of the NACC-UDS database. BMC Geriatr 2013;13:137.
[6] Komarova NL, Thalhauser CJ. High degree of heterogeneity in Alzheimer's disease
progression patterns. PLoS Comput Biol 2011 Nov;7:e1002251.
[7] Koedam EL, Lauffer V, van der Vlies AE, van der Flier WM, Scheltens P, Pijnenburg
YA. Early-versus late-onset Alzheimer's disease: more than age alone. J Alzheimers
Dis 2010;19:1401-1408.
[8] Schmidt C, Redyk K, Meissner B, et al. Clinical features of rapidly progressive Alz‐
heimer's disease. Dement Geriatr Cogn Disord 2010;29:371-378.
[9] de Leon MJ, Mosconi L, Blennow K, et al. Imaging and CSF studies in the preclinical
diagnosis of Alzheimer's disease. Ann N Y Acad Sci 2007 Feb;1097:114-145.
[10] Walhovd KB, Fjell AM, Brewer J, et al. Combining MR imaging, positron-emission
tomography, and CSF biomarkers in the diagnosis and prognosis of Alzheimer dis‐
ease. AJNR Am J Neuroradiol 2010 Feb;31:347-354.
[11] Boutoleau-Bretonniere C, Lebouvier T, Delaroche O, et al. Value of neuropsychologi‐
cal testing, imaging, and CSF biomarkers for the differential diagnosis and prognosis
of clinically ambiguous dementia. J Alzheimers Dis 2012;28:323-336.
[12] Shaffer JL, Petrella JR, Sheldon FC, et al. Predicting cognitive decline in subjects at
risk for Alzheimer disease by using combined cerebrospinal fluid, MR imaging, and
PET biomarkers. Radiology 2013 Feb;266:583-591.
[13] Edwards M, Balldin VH, Hall J, O'Bryant S. Combining Select Neuropsychological
Assessment with Blood-Based Biomarkers to Detect Mild Alzheimer's Disease: A
Molecular Neuropsychology Approach. J Alzheimers Dis 2014 Jun 10.
[14] Deutsche Gesellschaft für Psychiatrie PuNDDGfND. Demenzen. S3-Leitlinie, 2009.
[15] McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical di‐
agnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under
the auspices of Department of Health and Human Services Task Force on Alzheim‐
er's Disease. Neurology 1984 Jul;34:939-944.
[16] McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to
Alzheimer's disease: recommendations from the National Institute on Aging-Alz‐
heimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.
Alzheimers Dement 2011 May;7:263-269.
New Frontiers in Alzheimer's Disease Diagnosis
http://dx.doi.org/10.5772/59652
279
[17] Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alz‐
heimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007 Aug;
6:734-746.
[18] Albert MS, Dekosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment
due to Alzheimer's disease: recommendations from the National Institute on Aging-
Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's dis‐
ease. Alzheimers Dement 2011 May;7:270-279.
[19] Winblad B, Palmer K, Kivipelto M, et al. Mild cognitive impairment--beyond contro‐
versies, towards a consensus: report of the International Working Group on Mild
Cognitive Impairment. J Intern Med 2004 Sep;256:240-246.
[20] Petersen RC. Clinical practice. Mild cognitive impairment. N Engl J Med 2011 Jun
9;364:2227-2234.
[21] Loewenstein D. Assessment of Alzheimer´s Disease. Handbook on the Neuropsy‐
chology of Aging and Dementia. Springer, 2013:271-280.
[22] Jahn T. Neuropsychologie der Demenz. Lautenbacher S, Gauggel (Hrsg.): Neuropsy‐
chologie psychischer Störungen. Springer, 2010:360-381.
[23] Schmidtke K. Otto, M. Demenzen. Wallesch, CW, Förstl, H (Hrsg.) Thieme,
2012:203-227.
[24] Schmidtke K, Olbrich S. The Clock Reading Test: validation of an instrument for the
diagnosis of dementia and disorders of visuo-spatial cognition. Int Psychogeriatr 2007
Apr;19:307-321.
[25] Schmidtke K. Neuropsychologische Untersuchung bei Patienten mit Demenzver‐
dacht. In: Hüll M, ed., 26 ed Nervenheilkunde, 2007:651-658.
[26] Tsai PH, Teng E, Liu C, Mendez MF. Posterior cortical atrophy: evidence for discrete
syndromes of early-onset Alzheimer's disease. Am J Alzheimers Dis Other Demen 2011
Aug;26:413-418.
[27] Groh-Bordin C. Störungen der Visuellen Raumwahrnehmung und Raumkognition.
In: Kerkhoff G, ed. Sturm, W. et al. (Hrsg.): Lehrbuch der Klinischen Neuropsycholo‐
gie, Springer, 2009:500-512.
[28] Monsch AU, Bondi MW, Butters N, Salmon DP, Katzman R, Thal LJ. Comparisons of
verbal fluency tasks in the detection of dementia of the Alzheimer type. Arch Neurol
1992 Dec;49:1253-1258.
[29] Engel S. Kognitives Screening. In: Mück A LFR, ed. Demenzerkrankungen. Deutsch‐
er Ärzte-Verlag Mahlberg R, Gutzmann (Hrsg.). 2009.
[30] Beblo T. Neuropsychologie affektiver Störungen. Neuropsychologie psychischer
Störungen. 2. Auflage Lautenbacher, S, Gauggel, S (Hrsg.). 2010:211-218.
Alzheimer's Disease - Challenges for the Future280
[31] Beblo T. Neuropsychologie der Depression. In: Lautenbacher S, ed. Göttingen: Hog‐
refe, 2006.
[32] Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for
grading the cognitive state of patients for the clinician. J Psychiatr Res 1975 Nov;
12:189-198.
[33] Anthony JC, LeResche L, Niaz U, Von Korff MR, Folstein MF. Limits of the 'Mini-
Mental State' as a screening test for dementia and delirium among hospital patients.
Psychol Med 1982 May;12:397-408.
[34] Ivemeyer D. Demenztests in der Praxis. In: Zerfaß R, ed. München: Urban & Fischer,
2006.
[35] Kalbe E, Kessler J, Calabrese P, et al. DemTect: a new, sensitive cognitive screening
test to support the diagnosis of mild cognitive impairment and early dementia. Int J
Geriatr Psychiatry 2004 Feb;19:136-143.
[36] Aebi C. Validierung der neuropsychologischen Testbatterie CERAD-NP. Eine Multi-
Center Studie. Dissertation, Bassel 2002.: 2002.
[37] Barth S. Neuropsychologische Profile in der Demenzdiagnostik: Eine Untersuchung
mit der CERAD-NP-Testbatterie. In: Schönknecht PPJSJ, ed. Fortschritte Neurologie
Psychiatrie : 2005:1-9.
[38] Shulman KI. Clock-drawing: is it the ideal cognitive screening test? Int J Geriatr Psy‐
chiatry 2000 Jun;15:548-561.
[39] Schröder MR et al. Merkmalsanalyse von Uhrzeichnungen als Beitrag zur Diagnostik
der Demenz vom Alzheimer Typ. In: Hasse-Sander IMHHRMHJ, ed., 12 ed Zeits‐
chrift für Gerontopsychologie & -psychiatrie, 1999:55-66.
[40] Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumen‐
tal activities of daily living. Gerontologist 1969;9:179-186.
[41] Erzigkeit H, Lehfeld H, Pena-Casanova J, et al. The Bayer-Activities of Daily Living
Scale (B-ADL): results from a validation study in three European countries. Dement
Geriatr Cogn Disord 2001 Sep;12:348-358.
[42] Pfeffer RI, Kurosaki TT, Harrah CH, Jr., Chance JM, Filos S. Measurement of func‐
tional activities in older adults in the community. J Gerontol 1982 May;37:323-329.
[43] Yesavage JA, Brink TL, Rose TL, et al. Development and validation of a geriatric de‐
pression screening scale: a preliminary report. J Psychiatr Res 1982;17:37-49.
[44] Ortiz-Teran L. Currently Available Neuroimaging Approaches in Alzheimer Disease
(AD) Early Diagnosis. In: et al, ed. Suzanne de La Monte (Hg.): The Clinical Spec‐
trum of Alzheimer's Disease -The Charge Toward Comprehensive Diagnostic and
Therapeutic Strategies: InTech., 2011.
New Frontiers in Alzheimer's Disease Diagnosis
http://dx.doi.org/10.5772/59652
281
[45] de Leon MJ, George AE, Golomb J, et al. Frequency of hippocampal formation atro‐
phy in normal aging and Alzheimer's disease. Neurobiol Aging 1997 Jan;18:1-11.
[46] Wallesch C. Demenzen. 2., überarbeitete und erweiterte Auflage. Stuttgart: Thieme
(Referenzreihe Neurologie Herausgegeben von G. Deuschl, H.C. Diener, H.C. Hopf).,
2012.
[47] Reiser M. Radiologie. 3., vollst. überarb. u. erw. Aufl. In: et al, ed. Stuttgart: Thieme
(Duale Reihe)., 2011.
[48] Kinkingnehun S, Sarazin M, Lehericy S, Guichart-Gomez E, Hergueta T, Dubois B.
VBM anticipates the rate of progression of Alzheimer disease: a 3-year longitudinal
study. Neurology 2008 Jun 3;70:2201-2211.
[49] Thompson PM, Hayashi KM, de Zubicaray GI, et al. Mapping hippocampal and ven‐
tricular change in Alzheimer disease. Neuroimage 2004 Aug;22:1754-1766.
[50] Becker JT, Davis SW, Hayashi KM, et al. Three-dimensional patterns of hippocampal
atrophy in mild cognitive impairment. Arch Neurol 2006 Jan;63:97-101.
[51] Apostolova LG, Steiner CA, Akopyan GG, et al. Three-dimensional gray matter atro‐
phy mapping in mild cognitive impairment and mild Alzheimer disease. Arch Neurol
2007 Oct;64:1489-1495.
[52] Farid K, Caillat-Vigneron N, Sibon I. Is brain SPECT useful in degenerative dementia
diagnosis? J Comput Assist Tomogr 2011 Jan;35:1-3.
[53] Mosconi L, Berti V, Glodzik L, Pupi A, De SS, de Leon MJ. Pre-clinical detection of
Alzheimer's disease using FDG-PET, with or without amyloid imaging. J Alzheimers
Dis 2010;20:843-854.
[54] Matsuda H. Cerebral blood flow and metabolic abnormalities in Alzheimer's disease.
Ann Nucl Med 2001 Apr;15:85-92.
[55] Duran FL, Zampieri FG, Bottino CC, Buchpiguel CA, Busatto GF. Voxel-based inves‐
tigations of regional cerebral blood flow abnormalities in Alzheimer's disease using a
single-detector SPECT system. Clinics (Sao Paulo) 2007 Aug;62:377-384.
[56] Herholz K, Carter SF, Jones M. Positron emission tomography imaging in dementia.
Br J Radiol 2007 Dec;80 Spec No 2:S160-S167.
[57] Morris JC, Roe CM, Grant EA, et al. Pittsburgh compound B imaging and prediction
of progression from cognitive normality to symptomatic Alzheimer disease. Arch
Neurol 2009 Dec;66:1469-1475.
[58] Blennow K, Zetterberg H, Fagan AM. Fluid biomarkers in Alzheimer disease. Cold
Spring Harb Perspect Med 2012 Sep;2:a006221.
[59] Price JL, Morris JC. Tangles and plaques in nondemented aging and "preclinical"
Alzheimer's disease. Ann Neurol 1999 Mar;45:358-368.
Alzheimer's Disease - Challenges for the Future282
[60] Davies L, Wolska B, Hilbich C, et al. A4 amyloid protein deposition and the diagno‐
sis of Alzheimer's disease: prevalence in aged brains determined by immunocyto‐
chemistry compared with conventional neuropathologic techniques. Neurology 1988
Nov;38:1688-1693.
[61] Cutler RW, Spertell RB. Cerebrospinal fluid: a selective review. Ann Neurol 1982 Jan;
11:1-10.
[62] Fagan AM. CSF Biomarkers of Alzheimer's Disease: Impact on Disease Concept, Di‐
agnosis, and Clinical Trial Design. Advances in Geriatry 2014.
[63] Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma bio‐
markers in Alzheimer disease. Nat Rev Neurol 2010 Mar;6:131-144.
[64] Consensus report of the Working Group on: "Molecular and Biochemical Markers of
Alzheimer's Disease". The Ronald and Nancy Reagan Research Institute of the Alz‐
heimer's Association and the National Institute on Aging Working Group. Neurobiol
Aging 1998 Mar;19:109-116.
[65] Mattsson N, Zetterberg H, Hansson O, et al. CSF biomarkers and incipient Alzheimer
disease in patients with mild cognitive impairment. JAMA 2009 Jul 22;302:385-393.
[66] Kanai M, Matsubara E, Isoe K, et al. Longitudinal study of cerebrospinal fluid levels
of tau, A beta1-40, and A beta1-42(43) in Alzheimer's disease: a study in Japan. Ann
Neurol 1998 Jul;44:17-26.
[67] Shoji M, Matsubara E, Murakami T, et al. Cerebrospinal fluid tau in dementia disor‐
ders: a large scale multicenter study by a Japanese study group. Neurobiol Aging 2002
May;23:363-370.
[68] Visser PJ, Verhey F, Knol DL, et al. Prevalence and prognostic value of CSF markers
of Alzheimer's disease pathology in patients with subjective cognitive impairment or
mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lan‐
cet Neurol 2009 Jul;8:619-627.
[69] Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. Cerebrospinal fluid biomarker
signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 2009
Apr;65:403-413.
[70] Mattsson N, Zetterberg H, Blennow K. Lessons from Multicenter Studies on CSF Bio‐
markers for Alzheimer's Disease. Int J Alzheimers Dis 2010;2010.
[71] Hampel H, Teipel SJ, Fuchsberger T, et al. Value of CSF beta-amyloid1-42 and tau as
predictors of Alzheimer's disease in patients with mild cognitive impairment. Mol
Psychiatry 2004 Jul;9:705-710.
[72] Herukka SK, Hallikainen M, Soininen H, Pirttila T. CSF Abeta42 and tau or phos‐
phorylated tau and prediction of progressive mild cognitive impairment. Neurology
2005 Apr 12;64:1294-1297.
New Frontiers in Alzheimer's Disease Diagnosis
http://dx.doi.org/10.5772/59652
283
[73] Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Associa‐
tion between CSF biomarkers and incipient Alzheimer's disease in patients with mild
cognitive impairment: a follow-up study. Lancet Neurol 2006 Mar;5:228-234.
[74] Snider BJ, Fagan AM, Roe C, et al. Cerebrospinal fluid biomarkers and rate of cogni‐
tive decline in very mild dementia of the Alzheimer type. Arch Neurol 2009 May;
66:638-645.
[75] Hartmann T, Bieger SC, Bruhl B, et al. Distinct sites of intracellular production for
Alzheimer's disease A beta40/42 amyloid peptides. Nat Med 1997 Sep;3:1016-1020.
[76] Hampel H, Shen Y, Walsh DM, et al. Biological markers of amyloid beta-related
mechanisms in Alzheimer's disease. Exp Neurol 2010 Jun;223:334-346.
[77] Hoshi M, Sato M, Matsumoto S, et al. Spherical aggregates of beta-amyloid (amylos‐
pheroid) show high neurotoxicity and activate tau protein kinase I/glycogen syn‐
thase kinase-3beta. Proc Natl Acad Sci U S A 2003 May 27;100:6370-6375.
[78] Blennow K. Cerebrospinal fluid protein biomarkers for Alzheimer's disease. NeuroRx
2004 Apr;1:213-225.
[79] Hansson O, Zetterberg H, Buchhave P, et al. Prediction of Alzheimer's disease using
the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment. Dement
Geriatr Cogn Disord 2007;23:316-320.
[80] Vanmechelen E, Vanderstichele H, Hulstaert F, et al. Cerebrospinal fluid tau and be‐
ta-amyloid(1-42) in dementia disorders. Mech Ageing Dev 2001 Nov;122:2005-2011.
[81] Sjogren M, Minthon L, Davidsson P, et al. CSF levels of tau, beta-amyloid(1-42) and
GAP-43 in frontotemporal dementia, other types of dementia and normal aging. J
Neural Transm 2000;107:563-579.
[82] Tamaoka A, Sekijima Y, Matsuno S, Tokuda T, Shoji S, Ikeda SI. Amyloid beta pro‐
tein species in cerebrospinal fluid and in brain from patients with Down's syndrome.
Ann Neurol 1999 Dec;46:933.
[83] Strozyk D, Blennow K, White LR, Launer LJ. CSF Abeta 42 levels correlate with amy‐
loid-neuropathology in a population-based autopsy study. Neurology 2003 Feb
25;60:652-656.
[84] Riemenschneider M, Wagenpfeil S, Diehl J, et al. Tau and Abeta42 protein in CSF of
patients with frontotemporal degeneration. Neurology 2002 Jun 11;58:1622-1628.
[85] Tang W, Huang Q, Wang Y, Wang ZY, Yao YY. Assessment of CSF Abeta as an aid to
discriminating Alzheimer's disease from other dementias and mild cognitive impair‐
ment: A meta-analysis of 50 studies. J Neurol Sci 2014 Jul 15.
[86] Mehta PD, Pirttila T, Mehta SP, Sersen EA, Aisen PS, Wisniewski HM. Plasma and
cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer dis‐
ease. Arch Neurol 2000 Jan;57:100-105.
Alzheimer's Disease - Challenges for the Future284
[87] Schoonenboom NS, Mulder C, Van Kamp GJ, et al. Amyloid beta 38, 40, and 42 spe‐
cies in cerebrospinal fluid: more of the same? Ann Neurol 2005 Jul;58:139-142.
[88] Pijnenburg YA, Schoonenboom SN, Mehta PD, et al. Decreased cerebrospinal fluid
amyloid beta (1-40) levels in frontotemporal lobar degeneration. J Neurol Neurosurg
Psychiatry 2007 Jul;78:735-737.
[89] Gabelle A, Roche S, Geny C, et al. Decreased sAbetaPPbeta, Abeta38, and Abeta40
cerebrospinal fluid levels in frontotemporal dementia. J Alzheimers Dis
2011;26:553-563.
[90] Lewczuk P, Lelental N, Spitzer P, Maler JM, Kornhuber J. Amyloid-beta 42/40 Cere‐
brospinal Fluid Concentration Ratio in the Diagnostics of Alzheimer's Disease: Vali‐
dation of Two Novel Assays. J Alzheimers Dis 2014 Jul 30.
[91] Shoji M, Matsubara E, Kanai M, et al. Combination assay of CSF tau, A beta 1-40 and
A beta 1-42(43) as a biochemical marker of Alzheimer's disease. J Neurol Sci 1998 Jun
30;158:134-140.
[92] Spies PE, Slats D, Sjogren JM, et al. The cerebrospinal fluid amyloid beta42/40 ratio in
the differentiation of Alzheimer's disease from non-Alzheimer's dementia. Curr Alz‐
heimer Res 2010 Aug;7:470-476.
[93] Wiltfang J, Esselmann H, Bibl M, et al. Amyloid beta peptide ratio 42/40 but not A
beta 42 correlates with phospho-Tau in patients with low- and high-CSF A beta 40
load. J Neurochem 2007 May;101:1053-1059.
[94] Lewczuk P, Esselmann H, Otto M, et al. Neurochemical diagnosis of Alzheimer's de‐
mentia by CSF Abeta42, Abeta42/Abeta40 ratio and total tau. Neurobiol Aging 2004
Mar;25:273-281.
[95] Bombois S, Duhamel A, Salleron J, et al. A new decision tree combining Abeta 1-42
and p-Tau levels in Alzheimer's diagnosis. Curr Alzheimer Res 2013 May 1;10:357-364.
[96] Parnetti L, Chiasserini D, Eusebi P, et al. Performance of abeta1-40, abeta1-42, total
tau, and phosphorylated tau as predictors of dementia in a cohort of patients with
mild cognitive impairment. J Alzheimers Dis 2012;29:229-238.
[97] Holsinger RM, McLean CA, Collins SJ, Masters CL, Evin G. Increased beta-Secretase
activity in cerebrospinal fluid of Alzheimer's disease subjects. Ann Neurol 2004 Jun;
55:898-899.
[98] Zhong Z, Ewers M, Teipel S, et al. Levels of beta-secretase (BACE1) in cerebrospinal
fluid as a predictor of risk in mild cognitive impairment. Arch Gen Psychiatry 2007
Jun;64:718-726.
[99] Ewers M, Zhong Z, Burger K, et al. Increased CSF-BACE 1 activity is associated with
ApoE-epsilon 4 genotype in subjects with mild cognitive impairment and Alzheim‐
er's disease. Brain 2008 May;131:1252-1258.
New Frontiers in Alzheimer's Disease Diagnosis
http://dx.doi.org/10.5772/59652
285
[100] Zetterberg H, Andreasson U, Hansson O, et al. Elevated cerebrospinal fluid BACE1
activity in incipient Alzheimer disease. Arch Neurol 2008 Aug;65:1102-1107.
[101] Holsinger RM, Lee JS, Boyd A, Masters CL, Collins SJ. CSF BACE1 activity is in‐
creased in CJD and Alzheimer disease versus (corrected) other dementias. Neurology
2006 Aug 22;67:710-712.
[102] Ewers M, Cheng X, Zhong Z, et al. Increased CSF-BACE1 activity associated with de‐
creased hippocampus volume in Alzheimer's disease. J Alzheimers Dis
2011;25:373-381.
[103] Ye S, Huang Y, Mullendorff K, et al. Apolipoprotein (apo) E4 enhances amyloid beta
peptide production in cultured neuronal cells: apoE structure as a potential thera‐
peutic target. Proc Natl Acad Sci U S A 2005 Dec 20;102:18700-18705.
[104] Menting KW, Claassen JA. beta-secretase inhibitor; a promising novel therapeutic
drug in Alzheimer's disease. Front Aging Neurosci 2014;6:165.
[105] Fukumoto H, Tokuda T, Kasai T, et al. High-molecular-weight beta-amyloid oligom‐
ers are elevated in cerebrospinal fluid of Alzheimer patients. FASEB J 2010 Aug;
24:2716-2726.
[106] Santos AN, Ewers M, Minthon L, et al. Amyloid-beta oligomers in cerebrospinal flu‐
id are associated with cognitive decline in patients with Alzheimer's disease. J Alz‐
heimers Dis 2012;29:171-176.
[107] Holtta M, Hansson O, Andreasson U, et al. Evaluating amyloid-beta oligomers in
cerebrospinal fluid as a biomarker for Alzheimer's disease. PLoS One 2013;8:e66381.
[108] Gao CM, Yam AY, Wang X, et al. Abeta40 oligomers identified as a potential bio‐
marker for the diagnosis of Alzheimer's disease. PLoS One 2010;5:e15725.
[109] Salvadores N, Shahnawaz M, Scarpini E, Tagliavini F, Soto C. Detection of misfolded
Abeta oligomers for sensitive biochemical diagnosis of Alzheimer's disease. Cell Rep
2014 Apr 10;7:261-268.
[110] Pitschke M, Prior R, Haupt M, Riesner D. Detection of single amyloid beta-protein
aggregates in the cerebrospinal fluid of Alzheimer's patients by fluorescence correla‐
tion spectroscopy. Nat Med 1998 Jul;4:832-834.
[111] Fukumoto H, Asami-Odaka A, Suzuki N, Iwatsubo T. Association of A beta 40-posi‐
tive senile plaques with microglial cells in the brains of patients with Alzheimer's
disease and in non-demented aged individuals. Neurodegeneration 1996 Mar;5:13-17.
[112] Gravina SA, Ho L, Eckman CB, et al. Amyloid beta protein (A beta) in Alzheimer's
disease brain. Biochemical and immunocytochemical analysis with antibodies specif‐
ic for forms ending at A beta 40 or A beta 42(43). J Biol Chem 1995 Mar
31;270:7013-7016.
Alzheimer's Disease - Challenges for the Future286
[113] Ferrera D, Mazzaro N, Canale C, Gasparini L. Resting microglia react to Abeta42 fi‐
brils but do not detect oligomers or oligomer-induced neuronal damage. Neurobiol
Aging 2014 May 29.
[114] Englund H, Degerman GM, Brundin RM, et al. Oligomerization partially explains
the lowering of Abeta42 in Alzheimer's disease cerebrospinal fluid. Neurodegener Dis
2009;6:139-147.
[115] Herskovits AZ, Locascio JJ, Peskind ER, Li G, Hyman BT. A Luminex assay detects
amyloid beta oligomers in Alzheimer's disease cerebrospinal fluid. PLoS One
2013;8:e67898.
[116] Sancesario GM, Cencioni MT, Esposito Z, et al. The load of amyloid-beta oligomers is
decreased in the cerebrospinal fluid of Alzheimer's disease patients. J Alzheimers Dis
2012;31:865-878.
[117] Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from
the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 2007 Feb;8:101-112.
[118] Shankar GM, Li S, Mehta TH, et al. Amyloid-beta protein dimers isolated directly
from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 2008 Aug;
14:837-842.
[119] Lesne S, Koh MT, Kotilinek L, et al. A specific amyloid-beta protein assembly in the
brain impairs memory. Nature 2006 Mar 16;440:352-357.
[120] Sjogren M, Vanderstichele H, Agren H, et al. Tau and Abeta42 in cerebrospinal fluid
from healthy adults 21-93 years of age: establishment of reference values. Clin Chem
2001 Oct;47:1776-1781.
[121] Humpel C. Identifying and validating biomarkers for Alzheimer's disease. Trends Bi‐
otechnol 2011 Jan;29:26-32.
[122] Andreasen N, Minthon L, Davidsson P, et al. Evaluation of CSF-tau and CSF-Abeta42
as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol 2001
Mar;58:373-379.
[123] Hesse C, Rosengren L, Andreasen N, et al. Transient increase in total tau but not
phospho-tau in human cerebrospinal fluid after acute stroke. Neurosci Lett 2001 Jan
19;297:187-190.
[124] Stoeck K, Sanchez-Juan P, Gawinecka J, et al. Cerebrospinal fluid biomarker support‐
ed diagnosis of Creutzfeldt-Jakob disease and rapid dementias: a longitudinal multi‐
centre study over 10 years. Brain 2012 Oct;135:3051-3061.
[125] Buerger K, Otto M, Teipel SJ, et al. Dissociation between CSF total tau and tau pro‐
tein phosphorylated at threonine 231 in Creutzfeldt-Jakob disease. Neurobiol Aging
2006 Jan;27:10-15.
New Frontiers in Alzheimer's Disease Diagnosis
http://dx.doi.org/10.5772/59652
287
[126] Fagan AM, Head D, Shah AR, et al. Decreased cerebrospinal fluid Abeta(42) corre‐
lates with brain atrophy in cognitively normal elderly. Ann Neurol 2009 Feb;
65:176-183.
[127] Zetterberg H, Blennow K, Hanse E. Amyloid beta and APP as biomarkers for Alz‐
heimer's disease. Exp Gerontol 2010 Jan;45:23-29.
[128] Andreasen N, Vanmechelen E, Van d, V, et al. Cerebrospinal fluid tau protein as a
biochemical marker for Alzheimer's disease: a community based follow up study. J
Neurol Neurosurg Psychiatry 1998 Mar;64:298-305.
[129] Kaerst L, Kuhlmann A, Wedekind D, Stoeck K, Lange P, Zerr I. Cerebrospinal fluid
biomarkers in Alzheimer's disease, vascular dementia and ischemic stroke patients: a
critical analysis. J Neurol 2013 Nov;260:2722-2727.
[130] van Harten AC, Kester MI, Visser PJ, et al. Tau and p-tau as CSF biomarkers in de‐
mentia: a meta-analysis. Clin Chem Lab Med 2011 Mar;49:353-366.
[131] De R, V, Galloni E, Marcon M, et al. Analysis of combined CSF biomarkers in AD di‐
agnosis. Clin Lab 2014;60:629-634.
[132] Holtzman DM. CSF biomarkers for Alzheimer's disease: current utility and potential
future use. Neurobiol Aging 2011 Dec;32 Suppl 1:S4-S9.
[133] Sunderland T, Linker G, Mirza N, et al. Decreased beta-amyloid1-42 and increased
tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA 2003 Apr
23;289:2094-2103.
[134] Kaerst L, Kuhlmann A, Wedekind D, Stoeck K, Lange P, Zerr I. Using cerebrospinal
fluid marker profiles in clinical diagnosis of dementia with Lewy bodies, Parkinson's
disease, and Alzheimer's disease. J Alzheimers Dis 2014;38:63-73.
[135] Parnetti L, Farotti L, Eusebi P, et al. Differential role of CSF alpha-synuclein species,
tau, and Abeta42 in Parkinson's Disease. Front Aging Neurosci 2014;6:53.
[136] Kahle PJ, Jakowec M, Teipel SJ, et al. Combined assessment of tau and neuronal
thread protein in Alzheimer's disease CSF. Neurology 2000 Apr 11;54:1498-1504.
[137] Okamura N, Arai H, Maruyama M, et al. Combined Analysis of CSF Tau Levels and
((123)I)Iodoamphetamine SPECT in Mild Cognitive Impairment: Implications for a
Novel Predictor of Alzheimer's Disease. Am J Psychiatry 2002 Mar;159:474-476.
[138] Borroni B, Malinverno M, Gardoni F, et al. A combination of CSF tau ratio and mid‐
saggital midbrain-to-pons atrophy for the early diagnosis of progressive supranu‐
clear palsy. J Alzheimers Dis 2010;22:195-203.
[139] Hampel H, Buerger K, Zinkowski R, et al. Measurement of phosphorylated tau epito‐
pes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal
fluid study. Arch Gen Psychiatry 2004 Jan;61:95-102.
Alzheimer's Disease - Challenges for the Future288
[140] Tang W, Huang Q, Yao YY, Wang Y, Wu YL, Wang ZY. Does CSF p-tau help to dis‐
criminate Alzheimer's disease from other dementias and mild cognitive impairment?
A meta-analysis of the literature. J Neural Transm 2014 May 10.
[141] Hampel H, Blennow K, Shaw LM, Hoessler YC, Zetterberg H, Trojanowski JQ. Total
and phosphorylated tau protein as biological markers of Alzheimer's disease. Exp
Gerontol 2010 Jan;45:30-40.
[142] Sanchez-Juan P, Green A, Ladogana A, et al. CSF tests in the differential diagnosis of
Creutzfeldt-Jakob disease. Neurology 2006 Aug 22;67:637-643.
[143] Kremer A, Louis JV, Jaworski T, Van LF. GSK3 and Alzheimer's Disease: Facts and
Fiction... Front Mol Neurosci 2011;4:17.
[144] Llorens F, Zafar S, Ansoleaga B, et al. Subtype and regional regulation of prion bio‐
markers in sporadic Creutzfeldt-Jakob disease. Neuropathol Appl Neurobiol 2014 Aug
18.
[145] Riemenschneider M, Wagenpfeil S, Vanderstichele H, et al. Phospho-tau/total tau ra‐
tio in cerebrospinal fluid discriminates Creutzfeldt-Jakob disease from other demen‐
tias. Mol Psychiatry 2003 Mar;8:343-347.
[146] Schmidt C, Haik S, Satoh K, et al. Rapidly progressive Alzheimer's disease: a multi‐
center update. J Alzheimers Dis 2012;30:751-756.
[147] Kester MI, van der Vlies AE, Blankenstein MA, et al. CSF biomarkers predict rate of
cognitive decline in Alzheimer disease. Neurology 2009 Oct 27;73:1353-1358.
[148] Visser PJ, Verhey F, Knol DL, et al. Prevalence and prognostic value of CSF markers
of Alzheimer's disease pathology in patients with subjective cognitive impairment or
mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lan‐
cet Neurol 2009 Jul;8:619-627.
[149] Amor S, Peferoen LA, Vogel DY, et al. Inflammation in neurodegenerative diseases--
an update. Immunology 2014 Jun;142:151-166.
[150] Aguzzi A, Barres BA, Bennett ML. Microglia: scapegoat, saboteur, or something else?
Science 2013 Jan 11;339:156-161.
[151] Akiyama H, Barger S, Barnum S, et al. Inflammation and Alzheimer's disease. Neuro‐
biol Aging 2000 May;21:383-421.
[152] Alcolea D, Carmona-Iragui M, Suarez-Calvet M, et al. Relationship Between beta-
Secretase, Inflammation and Core Cerebrospinal Fluid Biomarkers for Alzheimer's
Disease. J Alzheimers Dis 2014 May 12.
[153] Llorens F, Lopez-Gonzalez I, Thune K, et al. Subtype and regional-specific neuroin‐
flammation in sporadic creutzfeldt-jakob disease. Front Aging Neurosci 2014;6:198.
New Frontiers in Alzheimer's Disease Diagnosis
http://dx.doi.org/10.5772/59652
289
[154] Stoeck K, Bodemer M, Zerr I. Pro- and anti-inflammatory cytokines in the CSF of pa‐
tients with Creutzfeldt-Jakob disease. J Neuroimmunol 2006 Mar;172:175-181.
[155] Stoeck K, Bodemer M, Ciesielczyk B, et al. Interleukin 4 and interleukin 10 levels are
elevated in the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Arch
Neurol 2005 Oct;62:1591-1594.
[156] Swardfager W, Lanctot K, Rothenburg L, Wong A, Cappell J, Herrmann N. A meta-
analysis of cytokines in Alzheimer's disease. Biol Psychiatry 2010 Nov 15;68:930-941.
[157] Rota E, Bellone G, Rocca P, Bergamasco B, Emanuelli G, Ferrero P. Increased intra‐
thecal TGF-beta1, but not IL-12, IFN-gamma and IL-10 levels in Alzheimer's disease
patients. Neurol Sci 2006 Apr;27:33-39.
[158] Tarkowski E, Andreasen N, Tarkowski A, Blennow K. Intrathecal inflammation pre‐
cedes development of Alzheimer's disease. J Neurol Neurosurg Psychiatry 2003 Sep;
74:1200-1205.
[159] Schuitemaker A, Dik MG, Veerhuis R, et al. Inflammatory markers in AD and MCI
patients with different biomarker profiles. Neurobiol Aging 2009 Nov;30:1885-1889.
[160] Wang KX, Denhardt DT. Osteopontin: role in immune regulation and stress respons‐
es. Cytokine Growth Factor Rev 2008 Oct;19:333-345.
[161] Comi C, Carecchio M, Chiocchetti A, et al. Osteopontin is increased in the cerebrospi‐
nal fluid of patients with Alzheimer's disease and its levels correlate with cognitive
decline. J Alzheimers Dis 2010;19:1143-1148.
[162] Sun Y, Yin XS, Guo H, Han RK, He RD, Chi LJ. Elevated osteopontin levels in mild
cognitive impairment and Alzheimer's disease. Mediators Inflamm 2013;2013:615745.
[163] Bornsen L, Khademi M, Olsson T, Sorensen PS, Sellebjerg F. Osteopontin concentra‐
tions are increased in cerebrospinal fluid during attacks of multiple sclerosis. Mult
Scler 2011 Jan;17:32-42.
[164] Verwey NA, Schuitemaker A, van der Flier WM, et al. Serum amyloid p component
as a biomarker in mild cognitive impairment and Alzheimer's disease. Dement Geriatr
Cogn Disord 2008;26:522-527.
[165] Naude PJ, Nyakas C, Eiden LE, et al. Lipocalin 2: novel component of proinflamma‐
tory signaling in Alzheimer's disease. FASEB J 2012 Jul;26:2811-2823.
[166] Alcolea D, Carmona-Iragui M, Suarez-Calvet M, et al. Relationship Between beta-
Secretase, Inflammation and Core Cerebrospinal Fluid Biomarkers for Alzheimer's
Disease. J Alzheimers Dis 2014 Jan 1;42:157-167.
[167] Perrin RJ, Craig-Schapiro R, Malone JP, et al. Identification and validation of novel
cerebrospinal fluid biomarkers for staging early Alzheimer's disease. PLoS One
2011;6:e16032.
Alzheimer's Disease - Challenges for the Future290
[168] Craig-Schapiro R, Perrin RJ, Roe CM, et al. YKL-40: a novel prognostic fluid biomark‐
er for preclinical Alzheimer's disease. Biol Psychiatry 2010 Nov 15;68:903-912.
[169] Antonell A, Mansilla A, Rami L, et al. Cerebrospinal Fluid Level of YKL-40 Protein in
Preclinical and Prodromal Alzheimer's Disease. J Alzheimers Dis 2014 Jul 2.
[170] Krol J, Loedige I, Filipowicz W. The widespread regulation of microRNA biogenesis,
function and decay. Nat Rev Genet 2010 Sep;11:597-610.
[171] Gascon E, Gao FB. Cause or Effect: Misregulation of microRNA Pathways in Neuro‐
degeneration. Front Neurosci 2012;6:48.
[172] Maciotta S, Meregalli M, Torrente Y. The involvement of microRNAs in neurodege‐
nerative diseases. Front Cell Neurosci 2013;7:265.
[173] Lehmann SM, Kruger C, Park B, et al. An unconventional role for miRNA: let-7 acti‐
vates Toll-like receptor 7 and causes neurodegeneration. Nat Neurosci 2012 Jun;
15:827-835.
[174] Salta E, De SB. Non-coding RNAs with essential roles in neurodegenerative disor‐
ders. Lancet Neurol 2012 Feb;11:189-200.
[175] Eacker SM, Dawson TM, Dawson VL. Understanding microRNAs in neurodegenera‐
tion. Nat Rev Neurosci 2009 Dec;10:837-841.
[176] Cheng L, Quek CY, Sun X, Bellingham SA, Hill AF. The detection of microRNA asso‐
ciated with Alzheimer's disease in biological fluids using next-generation sequencing
technologies. Front Genet 2013;4:150.
[177] McAlexander MA, Phillips MJ, Witwer KW. Comparison of Methods for miRNA Ex‐
traction from Plasma and Quantitative Recovery of RNA from Cerebrospinal Fluid.
Front Genet 2013;4:83.
[178] Pritchard CC, Cheng HH, Tewari M. MicroRNA profiling: approaches and consider‐
ations. Nat Rev Genet 2012 May;13:358-369.
[179] Weiland M, Gao XH, Zhou L, Mi QS. Small RNAs have a large impact: circulating
microRNAs as biomarkers for human diseases. RNA Biol 2012 Jun;9:850-859.
[180] Sala FC, Lau P, Salta E, et al. Reduced expression of hsa-miR-27a-3p in CSF of pa‐
tients with Alzheimer disease. Neurology 2013 Dec 10;81:2103-2106.
[181] Kiko T, Nakagawa K, Tsuduki T, Furukawa K, Arai H, Miyazawa T. MicroRNAs in
plasma and cerebrospinal fluid as potential markers for Alzheimer's disease. J Alz‐
heimers Dis 2014;39:253-259.
[182] Muller M, Kuiperij HB, Claassen JA, Kusters B, Verbeek MM. MicroRNAs in Alz‐
heimer's disease: differential expression in hippocampus and cell-free cerebrospinal
fluid. Neurobiol Aging 2014 Jan;35:152-158.
New Frontiers in Alzheimer's Disease Diagnosis
http://dx.doi.org/10.5772/59652
291
[183] Lukiw WJ, Zhao Y, Cui JG. An NF-kappaB-sensitive micro RNA-146a-mediated in‐
flammatory circuit in Alzheimer disease and in stressed human brain cells. J Biol
Chem 2008 Nov 14;283:31315-31322.
[184] Lukiw WJ, Dua P, Pogue AI, Eicken C, Hill JM. Upregulation of micro RNA-146a
(miRNA-146a), a marker for inflammatory neurodegeneration, in sporadic Creutz‐
feldt-Jakob disease (sCJD) and Gerstmann-Straussler-Scheinker (GSS) syndrome. J
Toxicol Environ Health A 2011;74:1460-1468.
[185] Li YY, Cui JG, Hill JM, Bhattacharjee S, Zhao Y, Lukiw WJ. Increased expression of
miRNA-146a in Alzheimer's disease transgenic mouse models. Neurosci Lett 2011 Jan
3;487:94-98.
[186] Iyer A, Zurolo E, Prabowo A, et al. MicroRNA-146a: a key regulator of astrocyte-
mediated inflammatory response. PLoS One 2012;7:e44789.
[187] Boldin MP, Taganov KD, Rao DS, et al. miR-146a is a significant brake on autoim‐
munity, myeloproliferation, and cancer in mice. J Exp Med 2011 Jun 6;208:1189-1201.
[188] Podlesniy P, Figueiro-Silva J, Llado A, et al. Low cerebrospinal fluid concentration of
mitochondrial DNA in preclinical Alzheimer disease. Ann Neurol 2013 Nov;
74:655-668.
[189] Schlotterbeck G, Ross A, Dieterle F, Senn H. Metabolic profiling technologies for bio‐
marker discovery in biomedicine and drug development. Pharmacogenomics 2006 Oct;
7:1055-1075.
[190] Czech C, Berndt P, Busch K, et al. Metabolite profiling of Alzheimer's disease cere‐
brospinal fluid. PLoS One 2012;7:e31501.
[191] Trushina E, Dutta T, Persson XM, Mielke MM, Petersen RC. Identification of altered
metabolic pathways in plasma and CSF in mild cognitive impairment and Alzheim‐
er's disease using metabolomics. PLoS One 2013;8:e63644.
[192] Kaddurah-Daouk R, Zhu H, Sharma S, et al. Alterations in metabolic pathways and
networks in Alzheimer's disease. Transl Psychiatry 2013;3:e244.
[193] Zetterberg H, Wilson D, Andreasson U, et al. Plasma tau levels in Alzheimer's dis‐
ease. Alzheimers Res Ther 2013;5:9.
[194] Hye A, Lynham S, Thambisetty M, et al. Proteome-based plasma biomarkers for Alz‐
heimer's disease. Brain 2006 Nov;129:3042-3050.
[195] Hu WT, Holtzman DM, Fagan AM, et al. Plasma multianalyte profiling in mild cog‐
nitive impairment and Alzheimer disease. Neurology 2012 Aug 28;79:897-905.
[196] Doecke JD, Laws SM, Faux NG, et al. Blood-based protein biomarkers for diagnosis
of Alzheimer disease. Arch Neurol 2012 Oct;69:1318-1325.
Alzheimer's Disease - Challenges for the Future292
[197] O'Bryant SE, Xiao G, Barber R, et al. A serum protein-based algorithm for the detec‐
tion of Alzheimer disease. Arch Neurol 2010 Sep;67:1077-1081.
[198] Ray S, Britschgi M, Herbert C, et al. Classification and prediction of clinical Alzheim‐
er's diagnosis based on plasma signaling proteins. Nat Med 2007 Nov;13:1359-1362.
[199] Bjorkqvist M, Ohlsson M, Minthon L, Hansson O. Evaluation of a previously sug‐
gested plasma biomarker panel to identify Alzheimer's disease. PLoS One
2012;7:e29868.
[200] Soares HD, Chen Y, Sabbagh M, Roher A, Schrijvers E, Breteler M. Identifying early
markers of Alzheimer's disease using quantitative multiplex proteomic immunoas‐
say panels. Ann N Y Acad Sci 2009 Oct;1180:56-67.
[201] Nagele E, Han M, Demarshall C, Belinka B, Nagele R. Diagnosis of Alzheimer's dis‐
ease based on disease-specific autoantibody profiles in human sera. PLoS One
2011;6:e23112.
[202] Burgos K, Malenica I, Metpally R, et al. Profiles of extracellular miRNA in cerebrospi‐
nal fluid and serum from patients with Alzheimer's and Parkinson's diseases corre‐
late with disease status and features of pathology. PLoS One 2014;9:e94839.
[203] Galimberti D, Villa C, Fenoglio C, et al. Circulating miRNAs as Potential Biomarkers
in Alzheimer's Disease. J Alzheimers Dis 2014 Jul 7.
[204] Tan L, Yu JT, Liu QY, et al. Circulating miR-125b as a biomarker of Alzheimer's dis‐
ease. J Neurol Sci 2014 Jan 15;336:52-56.
[205] Tan L, Yu JT, Tan MS, et al. Genome-wide serum microRNA expression profiling
identifies serum biomarkers for Alzheimer's disease. J Alzheimers Dis
2014;40:1017-1027.
[206] Wang Q, Li P, Li A, et al. Plasma specific miRNAs as predictive biomarkers for diag‐
nosis and prognosis of glioma. J Exp Clin Cancer Res 2012;31:97.
[207] Leidinger P, Backes C, Deutscher S, et al. A blood based 12-miRNA signature of Alz‐
heimer disease patients. Genome Biol 2013;14:R78.
[208] Schipper HM, Maes OC, Chertkow HM, Wang E. MicroRNA expression in Alzheim‐
er blood mononuclear cells. Gene Regul Syst Bio 2007;1:263-274.
[209] Hampel H, Lista S, Teipel SJ, et al. Perspective on future role of biological markers in
clinical therapy trials of Alzheimer's disease: a long-range point of view beyond 2020.
Biochem Pharmacol 2014 Apr 15;88:426-449.
[210] Hampel H, Frank R, Broich K, et al. Biomarkers for Alzheimer's disease: academic,
industry and regulatory perspectives. Nat Rev Drug Discov 2010 Jul;9:560-574.
[211] Vos SJ, Xiong C, Visser PJ, et al. Preclinical Alzheimer's disease and its outcome: a
longitudinal cohort study. Lancet Neurol 2013 Oct;12:957-965.
New Frontiers in Alzheimer's Disease Diagnosis
http://dx.doi.org/10.5772/59652
293
[212] Bateman RJ, Xiong C, Benzinger TL, et al. Clinical and biomarker changes in domi‐
nantly inherited Alzheimer's disease. N Engl J Med 2012 Aug 30;367:795-804.
[213] Jack CR, Jr., Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomark‐
ers of the Alzheimer's pathological cascade. Lancet Neurol 2010 Jan;9:119-128.
[214] Jack CR, Jr., Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in
Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet
Neurol 2013 Feb;12:207-216.
Alzheimer's Disease - Challenges for the Future294
